Academic Appointments


  • Sr Research Scientist-Basic Life, Pathology - Montine Lab

Professional Education


  • BA/BS, University of California, Davis, Psychology/Human Development (1993)
  • MA, California School of Professional Psychology, Clinical Psychology (1996)
  • Internship, Veterans Affairs Puget Sound Health Care System, Neuropsychology, Clinical Psychology (1999)
  • PhD, California School of Professional Psychology, Clinical Psychology (2000)
  • Postdoctoral Fellowship, University of Washington/ NIH/NIA T32 Fellowship, Neurobehavior, Neuroendocrinology, and Genetics of Alzheimer’s Disease (2004)

All Publications


  • Epigenomic profile of GBA1 in Parkinson's disease. Parkinsonism & related disorders Berson, E., Zaghroun, R., Santoro, M., Bukhari, S., Seong, D., Shu, C. H., Perna, A., James, T., Montine, K. S., Serrano, G. E., Beach, T. G., Keene, C. D., Chang, H. Y., Corces, M. R., Cholerton, B., Aghaeepour, N., Montine, T. J. 2025; 140: 108066

    Abstract

    While genome-wide association studies have identified GBA1 as a key gene contributing to disease severity and cognitive decline in PD, its molecular effects remain poorly understood.We used integrative bulk ATAC-seq across six brain regions from autopsied individuals with PD and varying genetic risk to characterize region- and cell type-specific molecular differences. Using Cellformer, an AI-based bulk ATAC-seq-deconvolution tool, we determined cell type-specific effects of GBA1 on PD disease progression and then validated our findings using whole transcriptome data from blood samples.Epigenomic differences between PD with ("GBA+"; n = 15) and without ("GBA-", n = 15) GBA1 variants were localized in substantia nigra. Nineteen chromatin-accessible regions strictly separated GBA+ from GBA-, including the promoter sites of key genes such as CACNA1C, EHMT1, and SLC25A48. The effect in GBA + spanned the main cell types in brain, and chromatin differences between GBA- and GBA + increased with neuropathologic progression of disease. Significant differences in the epigenomic profile in GBA+ were observed in neuronal cells (AUROC = 0.8, AUPRC = 0.8, P-value<0.0001). Validation in blood samples distinguished between GBA+ and GBA-subtypes, achieving AUROC values of 0.99. Over 5000 transcripts in blood cells distinguished GBA+ from GBA-, validating key genes and pathways from our epigenomic analysis of brain regions.Our study provides novel insights into the cell type-specific epigenomic and transcriptomic landscape of GBA+ and its molecular divergence from other PD subtypes, and highlights potential therapeutic targets for this genetically defined subset of PD.

    View details for DOI 10.1016/j.parkreldis.2025.108066

    View details for PubMedID 41033114

  • Neuropsychiatric symptom subtypes and dementia-associated neuropathologic change. Alzheimer's & dementia : the journal of the Alzheimer's Association Cholerton, B. A., Beecham, G. W., Reitz, C., De Vito, A. N., Cuccaro, M., Kukull, W. A., Montine, T. J., Huey, E. D. 2025; 21 (9): e70622

    Abstract

    Neuropsychiatric symptoms (NPS) are prevalent in clinically diagnosed Alzheimer's disease (AD), yet their etiology remains unclear. We assessed associations between NPS and neuropathologic features in dementia patients.Logistic regression analyses estimated associations between neuropathologic lesions and retroactively assigned NPS phenotypes (early and late psychosis [EPS, LPS], early and late affective symptoms [EAS, LAS]).EPS was associated with Lewy body (odds ratio [OR] = 2.4, p < 0.0001) and white matter (OR = 1.7, p < 0.0001) pathology. LPS was associated with moderate/severe neurofibrillary tangles (OR = 2.8, p < 0.0001), moderate/frequent neuritic plaques (OR = 2.3, p < 0.0001), Lewy bodies (OR = 1.9, p < 0.0001), and cerebral amyloid angiopathy (OR = 1.6, p < 0.0001). EAS was associated with white matter injury (OR = 3.4, p < 0.0001); EAS and LAS were associated with moderate/severe neurofibrillary tangles (ORs = 1.7, 1.9, p < 0.005). Risk for EPS, LPS, and EAS increased with total neuropathologic burden.NPS subtypes are differentially associated with AD/non-AD neuropathologic features, suggesting that efficiency of interventional targets may depend upon timing and type of NPS.Timing/nature of neuropsychiatric symptoms (NPS) had distinct associations with brain autopsy findings in the National Alzheimer's Coordinating Center. Increased odds for psychosis symptoms was associated with both Alzheimer's disease neuropathologic change (ADNC) and Lewy body dementia (LBD). Late psychosis symptoms (PS) was most strongly associated with ADNC, early PS most strongly with LBD. Early PS and affective symptoms were both associated with white matter disease.

    View details for DOI 10.1002/alz.70622

    View details for PubMedID 40990480

    View details for PubMedCentralID PMC12458904

  • Attention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations. Movement disorders : official journal of the Movement Disorder Society Biundo, R., Bezdicek, O., Cammisuli, D. M., Cholerton, B., Dalrymple-Alford, J. C., Edelstyn, N., Fiorenzato, E., Holker, E., Martinez-Horta, S., Martini, A., Santangelo, G., Segura, B., Siri, C., Troster, A., Mestre, T. A., Ferro, A. S., Hyczy de Siqueira Tosin, M., Skorvanek, M., Weintraub, D., Geurtsen, G. J., and the members of the MDS Clinical Outcome Assessment Scientific Evaluation Committee 2025

    Abstract

    BACKGROUND: Cognitive impairment in Parkinson's disease (PD) is a well-established non-motor complication that significantly affects the quality of life and well-being of both patients and care partners. To optimally detect mild cognitive impairment or dementia, extensive neuropsychological assessment is essential. A wide range of cognitive tests and clinical outcome assessments have been used in clinical settings, often without regard to their clinimetric quality.METHODS: We performed a literature review of tests assessing attention/working memory and executive domains in PD (tests on other domains are included in an accompanying review). The selected tests were evaluated for their clinimetric properties and categorized by a panel of experts as "recommended," "recommended with caveats," "suggested," or "listed" according to the International Parkinson and Movement Disorder Society Clinical Outcome Assessment Scientific Evaluation Committee guidelines.RESULTS: A total of 30 tests were reviewed. Eight tests were "recommended," including four tests assessing attention/working memory abilities (WAIS-IV Digit Span, Coding and Symbol Search subtests, and Trail Making Test) and four tests assessing executive abilities (WAIS-IV Similarities, Wisconsin Card Sorting Test, Fluency Tests, and Stroop Color-Word Test). These tests demonstrated good to excellent levels of reliability and validity, have normative datasets, and are sensitive to change. Eight other tests were "recommended with caveats", eleven were "suggested," and three were "listed."CONCLUSIONS: The recommended tests for attention/working memory and executive functioning in PD can guide PD cognitive assessment. Other tests were identified as potentially useful; however, caution is advised due to their clinimetric limitations. Further validation studies are required for these tests. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

    View details for DOI 10.1002/mds.30293

    View details for PubMedID 40678921

  • Parkinson's disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction. NPJ Parkinson's disease Wilson, E. N., Umans, J., Swarovski, M. S., Minhas, P. S., Mendiola, J. H., Midttun, Ø., Ulvik, A., Shahid-Besanti, M., Linortner, P., Mhatre, S. D., Wang, Q., Channappa, D., Corso, N. K., Tian, L., Fredericks, C. A., Kerchner, G. A., Plowey, E. D., Cholerton, B., Ueland, P. M., Zabetian, C. P., Gray, N. E., Quinn, J. F., Montine, T. J., Sha, S. J., Longo, F. M., Wolk, D. A., Chen-Plotkin, A., Henderson, V. W., Wyss-Coray, T., Wagner, A. D., Mormino, E. C., Aghaeepour, N., Poston, K. L., Andreasson, K. I. 2025; 11 (1): 96

    Abstract

    Recent studies demonstrate that Parkinson's disease (PD) is associated with dysregulated metabolic flux through the kynurenine pathway (KP), in which tryptophan is converted to kynurenine (KYN), and KYN is subsequently metabolized to neuroactive compounds quinolinic acid (QA) and kynurenic acid (KA). Here, we used mass-spectrometry to compare blood and cerebral spinal fluid (CSF) KP metabolites between 158 unimpaired older adults and 177 participants with PD. We found increased neuroexcitatory QA/KA ratio in both plasma and CSF of PD participants associated with peripheral and cerebral inflammation and vitamin B6 deficiency. Furthermore, increased QA tracked with CSF tau, CSF soluble TREM2 (sTREM2) and severity of both motor and non-motor PD clinical symptoms. Finally, PD patient subgroups with distinct KP profiles displayed distinct PD clinical features. These data validate the KP as a site of brain and periphery crosstalk, integrating B-vitamin status, inflammation and metabolism to ultimately influence PD clinical manifestation.

    View details for DOI 10.1038/s41531-025-00964-7

    View details for PubMedID 40287426

    View details for PubMedCentralID PMC12033312

  • Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations. Movement disorders : official journal of the Movement Disorder Society Bezdicek, O., Biundo, R., Boelema, S., Cammisuli, D. M., Cholerton, B., Cronin-Golomb, A., Dalrymple-Alford, J. C., Duits, A., Fellows, R., Gerstenecker, A., El Hachioui, H., Horáková, H., Koerts, J., Levin, B., Liepelt-Scarfone, I., Sarno, M., Mestre, T. A., Ferro, Á. S., de Siqueira Tosin, M. H., Skorvanek, M., Weintraub, D., Geurtsen, G. J. 2025

    Abstract

    Cognitive impairment in Parkinson's disease (PD) is a key non-motor complication during the disease course.A review of detailed cognitive instruments to detect mild cognitive impairment (PD-MCI) or dementia (PDD) is needed to establish optimal tests that facilitate diagnostic accuracy.We performed a systematic literature review of tests that assess memory, language including premorbid intelligence, and visuospatial domains (for tests of attention and executive functions see accompanying review) to determine suitability to assess cognition in PD. Based on in-depth scrutiny of psychometric and other relevant clinimetric properties, tests were rated as "recommended," "recommended with caveats," "suggested," or "listed" by the International Parkinson and Movement Disorder Society (IPMDS) panel of experts according to the IPMDS Clinical Outcome Assessment Scientific Evaluation Committee guidelines.We included 39 tests encompassing 48 outcome measures. Seven tests (different versions or subtests of the test counted once) were recommended, including four for memory, one for visuospatial domains, one for language (including three measures), and one for estimated premorbid intelligence. Furthermore, 10 tests (12 measures) were "recommended with caveats," 11 were "suggested," and 11 (15 measures) were "listed."Recommended neuropsychological tests in memory, visuospatial functions, and language are proposed to guide the assessment of cognitive impairment and its progression in PD-MCI and PDD, and for use in clinical trials to stratify participants or as outcome measures. Novel measures being developed will need extensive validation research to be "recommended." © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

    View details for DOI 10.1002/mds.30166

    View details for PubMedID 40145638

  • Biomarkers. Alzheimer's & dementia : the journal of the Alzheimer's Association Smith, A., Plastini, M. J., Ashton, N. J., Montoliu-Gaya, L., Wilson, E. N., Arslan, B., Young, C. B., Winer, J. R., Shahid, M., Vossler, H., Kerchner, G. A., Cholerton, B., Andreasson, K. I., Yutsis, M., Henderson, V. W., Montine, T. J., Tian, L., Mormino, E., Zetterberg, H., Poston, K. L., Abdelnour, C. 2024; 20 Suppl 2: e091458

    Abstract

    Lewy body disease (LBD) often co-occurs with Alzheimer's disease neuropathological change (ADNC), which can be detected using plasma pTau181 and pTau217. Few studies have investigated these biomarkers in LBD, nor have studies investigated plasma pTau217 in Parkinson's disease (PD) cognitively normal patients (LBD-CN), or in alpha-synuclein positive (asyn-positive) participants. Furthermore, uncertainties remain regarding LBD-specific cut-points for these biomarkers. We aimed to determine whether there is a difference in the diagnostic performance of plasma pTau181 and pTau217 for detecting ADNC and amyloidosis in LBD. We also determine whether cut-points for these biomarkers in LBD differ from those for AD. Finally, we conducted a sensitivity analysis in asyn-positive participants.We included 230 Stanford research participants: 110 cognitively normal (CN), 43 LBD-CN, 41 LBD with cognitive impairment (LBD-CI), and 36 AD. Plasma pTau181 was measured with the Lumipulse G platform, and pTau217 with the ALZpath pTau217 assay. A-syn positivity was assessed in CSF with SYNTap®. Diagnostic accuracy of pTau181 and pTau271 in distinguishing ADNC (determined by CSF pTau181/Aβ42) and amyloidosis (determined by CSF Aβ42/Aβ40 or amyloid-β PET) were evaluated with receiver-operating characteristic (ROC) analyses. The Youden index was used to determine optimal cut-points in distinguishing ADNC and amyloidosis, and the DeLong test to compare model performance.In the LBD-CI group, plasma pTau181 and pTau217 had similar diagnostic performance in distinguishing ADNC+ from ADNC- (Figure 1A). Similarly, in the LBD-CN and LBD-CI groups, both biomarkers had similar diagnostic performance in distinguishing Aβ+ from Aβ- participants (Figure 1B). However, in the sensitivity analysis, pTau217 outperformed pTau181 for detecting Aβ+ in asyn-positive participants (AUC: 0.88, 95%-CI: 0.77-1 vs 0.77, 95%-CI: 0.64-0.90, p=0.045) (Figure 2B). Finally, plasma pTau181 and pTau217 cut-points for detecting ADNC and amyloidosis in LBD differed from those for AD (Figures 1-3).We present, for the first time, the diagnostic accuracy of plasma pTau217 in LBD-CN and asyn-positive participants. Our results indicate that plasma pTau181 and pTau217 reliably detect concomitant ADNC and amyloidosis in LBD. Particularly, plasma pTau217 appears more sensitive for detecting amyloidosis in asyn-positive participants. Additionally, our findings underscore the importance of establishing LBD-specific cut-points for AD biomarkers.

    View details for DOI 10.1002/alz.091458

    View details for PubMedID 39785408

  • Parkinson's disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction. Research square Wilson, E., Umans, J., Swarovski, M., Minhas, P., Midttun, Ø., Ulvik, A. A., Shahid-Besanti, M., Linortner, P., Mhatre, S., Wang, Q., Channappa, D., Corso, N., Tian, L., Fredericks, C., Kerchner, G., Plowey, E., Cholerton, B., Ueland, P., Zabetian, C., Gray, N., Quinn, J., Montine, T., Sha, S., Longo, F., Wolk, D., Chen-Plotkin, A., Henderson, V., Wyss-Coray, T., Wagner, A., Mormino, E., Aghaeepour, N., Poston, K., Andreasson, K. 2024

    Abstract

    Parkinson's disease (PD) is a complex multisystem disorder clinically characterized by motor, non-motor, and premotor manifestations. Pathologically, PD involves neuronal loss in the substantia nigra, striatal dopamine deficiency, and accumulation of intracellular inclusions containing aggregates of α-synuclein. Recent studies demonstrate that PD is associated with dysregulated metabolic flux through the kynurenine pathway (KP), in which tryptophan is converted to kynurenine (KYN), and KYN is subsequently metabolized to neuroactive compounds quinolinic acid (QA) and kynurenic acid (KA). This multicenter study used highly sensitive liquid chromatography-tandem mass-spectrometry to compare blood and cerebral spinal fluid (CSF) KP metabolites between 158 unimpaired older adults and 177 participants with PD. Results indicate that increased neuroexcitatory QA/KA ratio in both plasma and CSF of PD participants associated with peripheral and cerebral inflammation and vitamin B6 deficiency. Furthermore, increased QA tracked with CSF tau and severity of both motor and non-motor PD clinical dysfunction. Importantly, plasma and CSF kynurenine metabolites classified PD participants with a high degree of accuracy (AUC = 0.897). Finally, analysis of metabolite data revealed subgroups with distinct KP profiles, and these were subsequently found to display distinct PD clinical features. Together, these data further support the hypothesis that the KP serves as a site of brain and periphery crosstalk, integrating B-vitamin status, inflammation and metabolism to ultimately influence PD clinical manifestation.

    View details for DOI 10.21203/rs.3.rs-4980210/v1

    View details for PubMedID 39399688

    View details for PubMedCentralID PMC11469709

  • Single-cell peripheral immunoprofiling of lewy body and Parkinson's disease in a multi-site cohort. Molecular neurodegeneration Phongpreecha, T., Mathi, K., Cholerton, B., Fox, E. J., Sigal, N., Espinosa, C., Reincke, M., Chung, P., Hwang, L. J., Gajera, C. R., Berson, E., Perna, A., Xie, F., Shu, C. H., Hazra, D., Channappa, D., Dunn, J. E., Kipp, L. B., Poston, K. L., Montine, K. S., Maecker, H. T., Aghaeepour, N., Montine, T. J. 2024; 19 (1): 59

    Abstract

    Multiple lines of evidence support peripheral organs in the initiation or progression of Lewy body disease (LBD), a spectrum of neurodegenerative diagnoses that include Parkinson's Disease (PD) without or with dementia (PDD) and dementia with Lewy bodies (DLB). However, the potential contribution of the peripheral immune response to LBD remains unclear. This study aims to characterize peripheral immune responses unique to participants with LBD at single-cell resolution to highlight potential biomarkers and increase mechanistic understanding of LBD pathogenesis in humans.In a case-control study, peripheral mononuclear cell (PBMC) samples from research participants were randomly sampled from multiple sites across the United States. The diagnosis groups comprise healthy controls (HC, n = 159), LBD (n = 110), Alzheimer's disease dementia (ADD, n = 97), other neurodegenerative disease controls (NDC, n = 19), and immune disease controls (IDC, n = 14). PBMCs were activated with three stimulants (LPS, IL-6, and IFNa) or remained at basal state, stained by 13 surface markers and 7 intracellular signal markers, and analyzed by flow cytometry, which generated 1,184 immune features after gating.The model classified LBD from HC with an AUROC of 0.87 ± 0.06 and AUPRC of 0.80 ± 0.06. Without retraining, the same model was able to distinguish LBD from ADD, NDC, and IDC. Model predictions were driven by pPLCγ2, p38, and pSTAT5 signals from specific cell populations under specific activation. The immune responses characteristic for LBD were not associated with other common medical conditions related to the risk of LBD or dementia, such as sleep disorders, hypertension, or diabetes.Quantification of PBMC immune response from multisite research participants yielded a unique pattern for LBD compared to HC, multiple related neurodegenerative diseases, and autoimmune diseases thereby highlighting potential biomarkers and mechanisms of disease.

    View details for DOI 10.1186/s13024-024-00748-2

    View details for PubMedID 39090623

    View details for PubMedCentralID 9739123

  • The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials. Neurology Young, C. B., Cholerton, B., Smith, A. M., Shahid-Besanti, M., Abdelnour, C., Mormino, E. C., Hu, S. C., Chung, K. A., Peterson, A., Rosenthal, L., Pantelyat, A., Dawson, T. M., Quinn, J., Zabetian, C. P., Montine, T. J., Poston, K. L. 2024; 103 (2): e209609

    Abstract

    Executive functioning is one of the first domains to be impaired in Parkinson disease (PD), and the majority of patients with PD eventually develop dementia. Thus, developing a cognitive endpoint measure specifically assessing executive functioning is critical for PD clinical trials. The objective of this study was to develop a cognitive composite measure that is sensitive to decline in executive functioning for use in PD clinical trials.We used cross-sectional and longitudinal follow-up data from PD participants enrolled in the PD Cognitive Genetics Consortium, a multicenter setting focused on PD. All PD participants with Trail Making Test, Digit Symbol, Letter-Number Sequencing, Semantic Fluency, and Phonemic Fluency neuropsychological data collected from March 2010 to February 2020 were included. Baseline executive functioning data were used to create the Parkinson's Disease Composite of Executive Functioning (PaCEF) through confirmatory factor analysis. We examined the changes in the PaCEF over time, how well baseline PaCEF predicts time to cognitive progression, and the required sample size estimates for PD clinical trials. PaCEF results were compared with the Montreal Cognitive Assessment (MoCA), individual tests forming the PaCEF, and tests of visuospatial, language, and memory functioning.A total of 841 participants (251 no cognitive impairment [NCI], 480 mild cognitive impairment [MCI], and 110 dementia) with baseline data were included, of which the mean (SD) age was 67.1 (8.9) years and 270 were women (32%). Five hundred forty five PD participants had longitudinal neuropsychological data spanning 9 years (mean [SD] 4.5 [2.2] years) and were included in analyses examining cognitive decline. A 1-factor model of executive functioning with excellent fit (comparative fit index = 0.993, Tucker-Lewis index = 0.989, and root mean square error of approximation = 0.044) was used to calculate the PaCEF. The average annual change in PaCEF ranged from 0.246 points per year for PD-NCI participants who remained cognitively unimpaired to -0.821 points per year for PD-MCI participants who progressed to dementia. For PD-MCI, baseline PaCEF, but not baseline MoCA, significantly predicted time to dementia. Sample size estimates were 69%-73% smaller for PD-NCI trials and 16%-19% smaller for PD-MCI trials when using the PaCEF rather than MoCA as the endpoint.The PaCEF is a sensitive measure of executive functioning decline in PD and will be especially beneficial for PD clinical trials.

    View details for DOI 10.1212/WNL.0000000000209609

    View details for PubMedID 38870440

  • Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease. Annals of neurology Abdelnour, C., Young, C. B., Shahid-Besanti, M., Smith, A., Wilson, E. N., Ramos Benitez, J., Vossler, H., Plastini, M. J., Winer, J. R., Kerchner, G. A., Cholerton, B., Andreasson, K. I., Henderson, V. W., Yutsis, M., Montine, T. J., Tian, L., Mormino, E. C., Poston, K. L. 2024

    Abstract

    To determine whether plasma phosphorylated-Tau181 (pTau181) could be used as a diagnostic biomarker of concurrent Alzheimer's disease neuropathologic change (ADNC) or amyloidosis alone, as well as a prognostic, monitoring, and susceptibility/risk biomarker for clinical outcomes in Lewy body disease (LBD).We studied 565 participants: 94 LBD with normal cognition, 83 LBD with abnormal cognition, 114 with Alzheimer's disease, and 274 cognitively normal. Plasma pTau181 levels were measured with the Lumipulse G platform. Diagnostic accuracy for concurrent ADNC and amyloidosis was assessed with Receiver Operating Characteristic curves in a subset of participants with CSF pTau181/Aβ42, and CSF Aβ42/Aβ40 or amyloid-β PET, respectively. Linear mixed effects models were used to examine the associations between baseline and longitudinal plasma pTau181 levels and clinical outcomes.Plasma pTau181 predicted concurrent ADNC and amyloidosis in LBD with abnormal cognition with 87% and 72% accuracy, respectively. In LBD patients with abnormal cognition, higher baseline plasma pTau181 was associated with worse baseline MoCA and CDR-SB, as well as accelerated decline in CDR-SB. Additionally, in this group, rapid increases in plasma pTau181 over 3 years predicted a faster decline in CDR-SB and memory. In LBD patients with normal cognition, there was no association between baseline or longitudinal plasma pTau181 levels and clinical outcomes; however, elevated pTau181 at baseline increased the risk of conversion to cognitive impairment.Our findings suggest that plasma pTau181 is a promising biomarker for concurrent ADNC and amyloidosis in LBD. Furthermore, plasma pTau181 holds potential as a prognostic, monitoring, and susceptibility/risk biomarker, predicting disease progression in LBD. ANN NEUROL 2024.

    View details for DOI 10.1002/ana.27003

    View details for PubMedID 38888142

  • Neuropathologic Burden and Dementia in Nonagenarians and Centenarians. Neurology Cholerton, B., Latimer, C. S., Crane, P. K., Corrada, M. M., Gibbons, L. E., Larson, E. B., Kawas, C. H., Keene, C. D., Montine, T. J. 2024; 102 (3): e208060

    Abstract

    The aim of this study was to compare 2 large clinicopathologic cohorts of participants aged 90+ and to determine whether the association between neuropathologic burden and dementia in these older groups differs substantially from those seen in younger-old adults.Autopsied participants from The 90+ Study and Adult Changes in Thought (ACT) Study community-based cohort studies were evaluated for dementia-associated neuropathologic changes. Associations between neuropathologic variables and dementia were assessed using logistic or linear regression, and the weighted population attributable fraction (PAF) per type of neuropathologic change was estimated.The 90+ Study participants (n = 414) were older (mean age at death = 97.7 years) and had higher amyloid/tau burden than ACT <90 (n = 418) (mean age at death = 83.5 years) and ACT 90+ (n = 401) (mean age at death = 94.2 years) participants. The ACT 90+ cohort had significantly higher rates of limbic-predominant age-related TDP-43 encephalopathy (LATE-NC), microvascular brain injury (μVBI), and total neuropathologic burden. Independent associations between individual neuropathologic lesions and odds of dementia were similar between all 3 groups, with the exception of μVBI, which was associated with increased dementia risk in the ACT <90 group only (odds ratio 1.5, 95% CI 1.2-1.8, p < 0.001). Weighted PAF scores indicated that eliminating μVBI, although more prevalent in ACT 90+ participants, would have little effect on dementia. Conversely, eliminating μVBI in ACT <90 could theoretically reduce dementia at a similar rate to that of AD neuropathologic change (weighted PAF = 6.1%, 95% CI 3.8-8.4, p = 0.001). Furthermore, reducing LATE-NC in The 90+ Study could potentially reduce dementia to a greater degree (weighted PAF = 5.1%, 95% CI 3.0-7.3, p = 0.001) than either ACT cohort (weighted PAFs = 1.69, 95% CI 0.4-2.7).Our results suggest that specific neuropathologic features may differ in their effect on dementia among nonagenarians and centenarians from cohorts with different selection criteria and study design. Furthermore, microvascular lesions seem to have a more significant effect on dementia in younger compared with older participants. The results from this study demonstrate that different populations may require distinct dementia interventions, underscoring the need for disease-specific biomarkers.

    View details for DOI 10.1212/WNL.0000000000208060

    View details for PubMedID 38175995

  • Developing Topics. Alzheimer's & dementia : the journal of the Alzheimer's Association Sudhakar, T. D., Levendovszky, S. R., Zabetian, C. P., Tsuang, D. W., Pillai, J. A., Rao, S. M., Oguh, O., Lippa, C., Lopez, O. L., Berman, S., Irwin, D. J., Galasko, D. R., Litvan, I., Marder, K., Honig, L. S., Fleisher, J. E., Galvin, J. E., Bozoki, A., Taylor, A., Sabbagh, M., Wint, D., Cholerton, B., Leverenz, J. B., Olson, V. 2023; 19 Suppl 24: e082764

    Abstract

    Hippocampal and amygdala subfields variably affect cognitive impairment in neurodegenerative diseases. Subfields of these regions can be well segmented using modern neuroimaging tools but their role in neurodegenerative disease is under active investigation. In this study, we identified hippocampal and amygdala subregions predictive of cognitive performance and motor symptoms severity measured by MoCA (Montreal Cognitive Assessment) and MDS-UPDRS III, respectively, in patients with dementia with Lewy Bodies (DLB).We selected all participants with probable DLB (N = 48, mean age = 71±7 years, 15% female) enrolled in the Dementia with Lewy Bodies Consortium (DLBC) as of July 2022, with concurrent measures of 3D T1 MRI sequence, MoCA, and MDS-UPDRS III scores. We performed cortical reconstruction and volumetric segmentation of hippocampal subfields and nuclei of the amygdala using FreeSurfer (v 7.2). We used combat harmonization to account for site and scanner differences. We trained and applied a bootstrapped, bidirectional stepwise regression model of 29 predictor variables comprised of sub-fields and mean cortical thickness against MoCA and MDS-UPDRS III, respectively, with an 80-20 train-test split ratio, and 5000 repetitions, corrected for age and sex.Subfield segmentation is shown in Figure 1A. The best fitting model for MoCA included mean cortical thickness, parasubiculum, hippocampal and amygdala transition area, corticoamygdaloid transition area, and CA3 body (Figure 1B, adjusted R2 = 0.51). The best fitting model for MDS-UPDRS III included the cortical nucleus of the amygdala and CA1 body (Figure 1C, adjusted R2 = 0.22). This model was considered a poor fit. We considered MoCA for further analysis and closely predicted scores in our 20% partitioned test sample (Figure 2A, R2 = 0.38).We report model-based selection of hippocampal and amygdala subfields to predict MoCA scores in DLB. Atrophy in these regions has been associated with global cognitive deficit in mild cognitive impairment and Alzheimer disease cohorts. The model fit for MDS-UPDRS III scores was poor, providing evidence that these brain regions do not serve a role in motor control.

    View details for DOI 10.1002/alz.082764

    View details for PubMedID 39120947

  • Quantitative estimate of cognitive resilience and its medical and genetic associations. Alzheimer's research & therapy Phongpreecha, T., Godrich, D., Berson, E., Espinosa, C., Kim, Y., Cholerton, B., Chang, A. L., Mataraso, S., Bukhari, S. A., Perna, A., Yakabi, K., Montine, K. S., Poston, K. L., Mormino, E., White, L., Beecham, G., Aghaeepour, N., Montine, T. J. 2023; 15 (1): 192

    Abstract

    We have proposed that cognitive resilience (CR) counteracts brain damage from Alzheimer's disease (AD) or AD-related dementias such that older individuals who harbor neurodegenerative disease burden sufficient to cause dementia remain cognitively normal. However, CR traditionally is considered a binary trait, capturing only the most extreme examples, and is often inconsistently defined.This study addressed existing discrepancies and shortcomings of the current CR definition by proposing a framework for defining CR as a continuous variable for each neuropsychological test. The linear equations clarified CR's relationship to closely related terms, including cognitive function, reserve, compensation, and damage. Primarily, resilience is defined as a function of cognitive performance and damage from neuropathologic damage. As such, the study utilized data from 844 individuals (age = 79 ± 12, 44% female) in the National Alzheimer's Coordinating Center cohort that met our inclusion criteria of comprehensive lesion rankings for 17 neuropathologic features and complete neuropsychological test results. Machine learning models and GWAS then were used to identify medical and genetic factors that are associated with CR.CR varied across five cognitive assessments and was greater in female participants, associated with longer survival, and weakly associated with educational attainment or APOE ε4 allele. In contrast, damage was strongly associated with APOE ε4 allele (P value < 0.0001). Major predictors of CR were cardiovascular health and social interactions, as well as the absence of behavioral symptoms.Our framework explicitly decoupled the effects of CR from neuropathologic damage. Characterizations and genetic association study of these two components suggest that the underlying CR mechanism has minimal overlap with the disease mechanism. Moreover, the identified medical features associated with CR suggest modifiable features to counteract clinical expression of damage and maintain cognitive function in older individuals.

    View details for DOI 10.1186/s13195-023-01329-z

    View details for PubMedID 37926851

    View details for PubMedCentralID 6410486

  • Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics Perna, A., Montine, K. S., White, L. R., Montine, T. J., Cholerton, B. A. 2023

    Abstract

    Neurodegenerative dementia can result from multiple underlying abnormalities, including neurotransmitter imbalances, protein aggregation, and other neurotoxic events. A major complication in identifying effective treatment targets is the frequent co-occurrence of multiple neurodegenerative processes, occurring either in parallel or sequentially. The path towards developing effective treatments for Alzheimer's disease (AD) and other dementias has been relatively slow and until recently has focused on disease symptoms. Aducanumab and lecanemab, recently approved by the FDA, are meant to target disease structures but have only modest benefit on symptom progression and remain unproven in reversing or preventing dementia. A third, donanemab, appears more promising but awaits FDA approval. Ongoing trials include potential cognition enhancers, new combinations of known drugs for synergistic effects, prodrugs with less toxicity, and increasing interest in drugs targeting neuroinflammation or microbiome. Scientific and technological advances offer the opportunity to move in new therapy directions, such as modifying microglia to prevent or suppress underlying disease. A major challenge, however, is that underlying comorbidities likely influence the effectiveness of therapies. Indeed, the full range of comorbidity, today only definitively identified postmortem, likely contributes to failed clinical trials and overmedication of older adults, since it is difficult to exclude (during life) people unlikely to respond. Our current knowledge thus signals that a paradigm shift towards individualized and multimodal treatments is necessary to effectively advance the field of dementia therapeutics.

    View details for DOI 10.1007/s13311-023-01441-w

    View details for PubMedID 37733209

    View details for PubMedCentralID 3312024

  • Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia NEUROTHERAPEUTICS Perna, A., Montine, K. S., White, L. R., Montine, T. J., Cholerton, B. A. 2023
  • Neuropathologic Changes of Alzheimer's Disease and Related Dementias: Relevance to Future Prevention. Journal of Alzheimer's disease : JAD White, L. R., Corrada, M. M., Kawas, C. H., Cholerton, B. A., Edland, S. E., Flanagan, M. E., Montine, T. J. 2023

    Abstract

    BACKGROUND: Decedents with late-life dementia are often found at autopsy to have vascular pathology, cortical Lewy bodies, hippocampal sclerosis, and/or TDP-43 encephalopathy alone or with concurrent Alzheimer's disease (AD) lesions. Nonetheless, it is commonly believed that AD neuropathologic changes (NC) are the dominant or exclusive drivers of late-life dementia.OBJECTIVE: Assess associations of end-of-life cognitive impairment with any one or any combination of five distinct NC. Assess impairment prevalence among subjects having natural resistance to each type of NC.METHODS: Brains from 1,040 autopsied participants of the Honolulu-Asia Study, the Nun Study, and the 90 + Study were examined for NC of AD, Lewy body dementia, microvascular brain injury, hippocampal sclerosis, and limbic predominate TDP-43 encephalopathy. Associations with impairment were assessed for each NC and for NC polymorbidity (variable combinations of 2-5 concurrent NC).RESULTS: Among 387 autopsied decedents with severe cognitive impairment, 20.4% had only AD lesions (ADNC), 25.3% had ADNC plus 1 other NC, 11.1% had ADNC plus 2 or more other NC, 28.7% had no ADNC but 1-4 other NC, and 14.5% had no/negligible NC. Combinations of any two, three, or four NC were highly frequent among the impaired. Natural resistance to ADNC or any other single NC had a modest impact on overall cohort impairment levels.CONCLUSION: Polymorbidity involving 1-5 types of concurrent NC is a dominant neuropathologic feature of AD and related dementias. This represents a daunting challenge to future prevention and could explain failures of prior preventive intervention trials and of efforts to identify risk factors.

    View details for DOI 10.3233/JAD-230331

    View details for PubMedID 37522210

  • Associations between baseline cognitive status and motor outcomes after treadmill training in people with Parkinson's disease: a pilot study. Disability and rehabilitation Amin, R. M., Phillips, J. J., Humbert, A. T., Cholerton, B. A., Short, V. D., Smith, M. J., Zabetian, C. P., Mata, I. F., Kelly, V. E. 2023: 1-10

    Abstract

    PURPOSE: To determine the effect of baseline cognition on gait outcomes after a treadmill training program for people with Parkinson's disease (PD).METHODS: This pilot clinical trial involved people with PD who were classified as having no cognitive impairment (PD-NCI) or mild cognitive impairment (PD-MCI). Baseline executive function and memory were assessed. The intervention was a 10-week gait training program (twice-weekly treadmill sessions), with structured speed and distance progression and verbal cues for gait quality. Response to intervention was assessed by gait speed measured after week 2 (short-term) and week 10 (long-term).RESULTS: Participants (n=19; 12 PD-NCI, 7 PD-MCI) had a mean (standard deviation) age of 66.5 (6.3) years, disease duration of 8.8 (6.3) years, and MDS-UPDRS III score of 21.3 (10.7). Gait speed increased at short-term and long-term assessments. The response did not differ between PD-NCI and PD-MCI groups; however, better baseline memory performance and milder PD motor severity were independently associated with greater improvements in gait speed in unadjusted and adjusted models.CONCLUSIONS: These findings suggest that memory impairments and more severe motor involvement can influence the response to gait rehabilitation in PD and highlight the need for treatments optimized for people with greater cognitive and motor impairment.IMPLICATIONS FOR REHABILITATIONCognitive deficits in Parkinson's disease (PD) could impact motor learning and gait rehabilitation, yet little is known about the effects of cognitive impairments on the response to rehabilitation in people with PD.This study demonstrates that the response to gait rehabilitation did not differ between people with PD who had no cognitive impairment and those with mild cognitive impairment.Across all participants, better baseline memory was associated with greater improvements in gait speed.Rehabilitation professionals should be mindful of PD severity, as those with more substantial memory and motor impairments may require additional dosing or support to maximize gait training benefits.

    View details for DOI 10.1080/09638288.2023.2189318

    View details for PubMedID 37010072

  • Illusory Responses across the Lewy Body Disease Spectrum ANNALS OF NEUROLOGY Shahid, M., Rawls, A., Ramirez, V., Ryman, S., Santini, V. E., Yang, L., Sha, S. J., Hall, J. N., Montine, T. J., Lin, A., Tian, L., Henderson, V. W., Cholerton, B., Yutsis, M., Poston, K. L. 2023

    View details for DOI 10.1002/ana.26574

    View details for Web of Science ID 000925056000001

  • Prediction of neuropathologic lesions from clinical data. Alzheimer's & dementia : the journal of the Alzheimer's Association Phongpreecha, T., Cholerton, B., Bhukari, S., Chang, A. L., De Francesco, D., Thuraiappah, M., Godrich, D., Perna, A., Becker, M. G., Ravindra, N. G., Espinosa, C., Kim, Y., Berson, E., Mataraso, S., Sha, S. J., Fox, E. J., Montine, K. S., Baker, L. D., Craft, S., White, L., Poston, K. L., Beecham, G., Aghaeepour, N., Montine, T. J. 2023

    Abstract

    Post-mortem analysis provides definitive diagnoses of neurodegenerative diseases; however, only a few can be diagnosed during life.This study employed statistical tools and machine learning to predict 17 neuropathologic lesions from a cohort of 6518 individuals using 381 clinical features (Table S1). The multisite data allowed validation of the model's robustness by splitting train/test sets by clinical sites. A similar study was performed for predicting Alzheimer's disease (AD) neuropathologic change without specific comorbidities.Prediction results show high performance for certain lesions that match or exceed that of research annotation. Neurodegenerative comorbidities in addition to AD neuropathologic change resulted in compounded, but disproportionate, effects across cognitive domains as the comorbidity number increased.Certain clinical features could be strongly associated with multiple neurodegenerative diseases, others were lesion-specific, and some were divergent between lesions. Our approach could benefit clinical research, and genetic and biomarker research by enriching cohorts for desired lesions.

    View details for DOI 10.1002/alz.12921

    View details for PubMedID 36681388

  • Gait and balance in apolipoprotein Ɛ4 allele carriers in older adults and Parkinson's disease. Clinical parkinsonism & related disorders Morris, R., Martini, D. N., Kelly, V. E., Smulders, K., Ramsey, K., Hiller, A., Chung, K. A., Hu, S., Zabetian, C. P., Poston, K. L., Mata, I. F., Edwards, K. L., Lapidus, J., Cholerton, B., Montine, T. J., Quinn, J. F., Horak, F. 2023; 9: 100201

    Abstract

    Background: Gait and balance impairments are among the most troublesome and heterogeneous in Parkinson's disease (PD). This heterogeneity may, in part, reflect genetic variation. The apolipoprotein E (APOE) gene has three major allelic variants (epsilon2, epsilon3 and epsilon4). Previous work has demonstrated that older adult (OA) APOE epsilon4 carriers demonstrate gait deficits. This study compared gait and balance measures between APOE epsilon4 carriers and non-carriers in both OA and PD.Methods: 334 people with PD (81 APOE epsilon4 carriers and 253 non-carriers) and 144 OA (41 carriers and 103 non-carriers) were recruited. Gait and balance were assessed using body-worn inertial sensors. Two-way analyses of covariance (ANCOVA) compared gait and balance characteristics between APOE epsilon4 carriers and non-carriers in people with PD and OA, controlling for age, gender, and testing site.Results: Gait and balance were worse in people with PD compared to OA. However, there were no differences between APOE epsilon4 carriers and non-carriers in either the OA or PD group. In addition, there were no significant group (OA/PD) by APOE epsilon4 status (carrier/non-carrier) interaction effects for any measures of gait or balance.Conclusions: Although we found expected impairments in gait and balance in PD compared to OA, gait and balance characteristics did not differ between APOE epsilon4 carriers and non-carriers in either group. While APOE status did not impact gait and balance in this cross-sectional study, future work is needed to determine whether progression of gait and balance deficits is faster in PD APOE Ɛ4 carriers.

    View details for DOI 10.1016/j.prdoa.2023.100201

    View details for PubMedID 37252677

  • Illusory responses across the Lewy body disease spectrum Shahid, M., Rawls, A., Ramirez, V., Ryman, S., Santini, V., Yang, L., Sha, S., Hall, J., Montine, T., Lin, A., Tian, L., Henderson, V., Cholerton, B., Yutsis, M., Poston, K. WILEY. 2022: S364-S365

    Abstract

    To study pareidolias, or perceived meaningful objects in a meaningless stimulus, in patients across the Lewy body (LB) disease spectrum, where most do not report hallucinations or delusions.We studied illusory responses on the Noise Pareidolia Task in 300 participants [38 cognitively-impaired LB, 65 cognitively-unimpaired LB, 51 Alzheimer's disease-spectrum (AD-s), 146 Controls]. Pairwise between-group comparisons examined how diagnosis impacts the number of illusory responses. Ordinal regression analysis compared the number of illusory responses across diagnosis groups, adjusting for age, sex, and education. Analyses were repeated after removing participants with reported hallucinations or delusions.Cognitively-impaired LB participants were 12.3, 4.9, and 4.6 times more likely than Control, cognitively-unimpaired LB, and AD-s participants, respectively, to endorse illusory responses. After adjusting for age, sex and education, the probability of endorsing one or more illusory response was 61% in the cognitively-impaired LB group, compared to 26% in AD-s, 25% in cognitively-unimpaired LB, and 12% in Control participants. All results were similar after repeated analysis only in participants without hallucinations or delusions. In LB without hallucinations or delusions, 52% with mild cognitive impairment and 66.7% with dementia endorsed at least one illusory response.We found illusory responses are common in cognitively impaired LB patients, including those without any reported psychosis. Our data suggest that, prior to the onset of hallucinations and delusions, the Noise Pareidolia Task can easily be used to screen for unobtrusive pareidolias in all LB patients. This article is protected by copyright. All rights reserved.

    View details for Web of Science ID 000859942301355

    View details for PubMedID 36511519

  • Cognition as a mediator for gait and balance impairments in GBA-related Parkinson's disease. NPJ Parkinson's disease Morris, R., Martini, D. N., Ramsey, K., Kelly, V. E., Smulders, K., Hiller, A., Chung, K. A., Hu, S., Zabetian, C. P., Poston, K. L., Mata, I. F., Edwards, K. L., Lapidus, J., Cholerton, B., Montine, T. J., Quinn, J. F., Horak, F. 2022; 8 (1): 78

    Abstract

    The extent to which the heterogeneity of gait and balance problems in PD may be explained by genetic variation is unknown. Variants in the glucocerebrosidase (GBA) gene are the strongest known genetic risk factor for PD and are associated with greater motor and cognitive severity. However, the impact of GBA variants on comprehensive measures of gait and balance and their relationship to cognition remains unknown. We aimed to determine differences in gait and balance impairments in those with and without GBA variants (mutation carriers and E326K polymorphism) and explore direct and indirect effects of GBA status on gait, balance, and cognition. 332 participants, 43 of whom had GBA variants, were recruited. Participants completed a comprehensive, objective assessment of gait and standing balance using body-worn inertial sensors. Group differences in gait and balance between PD with and without GBA variants were assessed with linear regression, adjusting for age, gender, clinical testing site, disease duration, and apolipoprotein E (APOE) ɛ4 status. Structural equation modeling (SEM) explored direct relationships between GBA status and gait and balance and indirect relationships between GBA status and gait and balance via cognition. The GBA variant group had more impaired gait (pace and variability) and balance (sway area/jerk and sway velocity), than the non-GBA variant group. SEM demonstrated cognition as a mediator of GBA status on gait and balance. The close relationships among GBA, gait/balance, and cognition suggest potential for novel therapeutics to target the GBA pathway and/or cognition to improve mobility in PD GBA variants.

    View details for DOI 10.1038/s41531-022-00344-5

    View details for PubMedID 35725575

  • Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest-Old. Neurology Montine, T. J., Corrada, M. M., Kawas, C., Bukhari, S., White, L., Tian, L., Cholerton, B. 2022

    Abstract

    BACKGROUND AND OBJECTIVES: Age is the largest risk factor for dementia. However, dementia is not universal, even among the oldest-old age groups. Following contemporary neuropathologic guidelines, our objectives were to describe the key neuropathologic lesions and their associations with antemortem cognition in oldest-old individuals.METHODS: Participants were those enrolled in The 90+ Study, a longitudinal, population-based study of aging/dementia in the oldest-old, who agreed to postmortem brain examination. All autopsied brains as of December 2020 were evaluated for prevalence of Alzheimer's disease neuropathologic change (ADNC) and non-ADNC neuropathologic comorbidities. Associations between neuropathologic lesions or total neuropathologic burden score (sum of the individual scores) and cognition were assessed using multinomial logistic regression and multiple linear regression. Separate regression analyses evaluated relationships between limbic-predominant age-related TDP-43 encephalopathy (LATE-NC) and hippocampal sclerosis (HS) or ADNC/primary age-related tauopathy (PART). Resistance, or failure to develop ADNC/PART, and resilience, inferred from higher than expected cognitive functioning, were evaluated in the presence or absence of non-ADNC neuropathologic features.RESULTS: The most common neuropathologic features in the sample (n=367) were ADNC/PART-related. Increased dementia odds were associated with elevated total neuropathologic burden (OR=1.5 [95% CI 1.3-1.7] p<0.0001), beta amyloid (OR=1.6 [95% CI 1.2-2.0] p<0.0001), neurofibrillary tangles (OR=2.6 [95% CI 1.7-4.1] p<0.0001), and LATE-NC (OR=2.3 [95% CI 1.7-3.1] p<0.0001), correcting for multiple comparisons. LATE-NC was associated with dementia with (OR=6.1 [95% CI 2.0-18.7] p=0.002) and without (OR=5.0 [95% CI 2.6-9.7] p<0.0001) co-occurring HS, and increased the odds of dementia among participants with ADNC (OR=5.0 [95% CI 2.7-9.2] p<0.0001). Resistance to moderate/severe ADNC/PART was rare (3%), but resilience to ADNC/PART was not (55%). Resilience was rarer in the presence of non-ADNC comorbid lesions, particularly LATE-NC. Among those with moderate/severe ADNC/PART, dementia odds increased with each non-ADNC comorbid lesion (e.g., 1 lesion: OR=2.4 [95% CI 1.3-4.5] p<0.005; 2 lesions: OR=5.9 [95% CI 2.8-12.3] p<0.0001).CONCLUSION: These results highlight the importance of non-ADNC neuropathologic comorbidity, predominantly LATE-NC, to cognition in the oldest-old. Given the cumulative effects of non-ADNC comorbid neuropathologic abnormalities, reducing their prevalence, especially LATE-NC, will be vital to the ultimate goal of reducing dementia burden in the oldest-old individuals.

    View details for DOI 10.1212/WNL.0000000000200832

    View details for PubMedID 35705500

  • Associations between Baseline Cognitive Function and Gait Outcomes after Treadmill Training in Parkinson disease Amin, R., Phillips, J., Humbert, A., Cholerton, B., Zabetian, C., Mata, I., Kelly, V. LIPPINCOTT WILLIAMS & WILKINS. 2022
  • Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson's disease. Journal of clinical and experimental neuropsychology Cholerton, B. A., Poston, K. L., Yang, L., Rosenthal, L. S., Dawson, T. M., Pantelyat, A., Edwards, K. L., Tian, L., Quinn, J. F., Chung, K. A., Hiller, A. L., Hu, S., Montine, T. J., Zabetian, C. P. 2021: 1-12

    Abstract

    Introduction: Parkinson's disease (PD) is associated with a range of cognitive deficits. Few studies have carefully examined the subtle impacts of PD on cognition among patients who do not meet formal criteria for MCI or dementia. The aim of the current study was thus to describe the impact of PD on cognition in those without cognitive impairment in a well-characterized cohort.Methods: Non-cognitively impaired participants (122 with PD, 122 age- and sex-matched healthy volunteers) underwent extensive cognitive testing. Linear regression analyses compared diagnostic group performance across cognitive measures. For cognitive tasks that were significantly different between groups, additional analyses examined group differences restricting the group inclusion to PD participants with mild motor symptoms or disease duration less than 10years.Results: Processing speed and semantic verbal fluency were significantly lower in the PD group (B =-3.77, 95% CIs [-5.76 to -1.77], p <.001, and B =-2.02, 95% CIs [-3.12, -0.92], p <.001, respectively), even after excluding those with moderate to severe motor symptoms (B =-2.73, 95% CIs [-4.94 to -0.53], p =.015 and B =-2.11, 95% CIs [-3.32 to -0.91], p <.001, respectively) or longer disease duration (B =-3.89, 95% CIs [-6.14 to -1.63], p <.001 and B =-1.58, 95% CIs [-2.78 to -0.37], p =.010, respectively). Semantic verbal fluency remained significantly negatively associated with PD diagnosis after controlling for processing speed (B =-1.66, 95% CIs [-2.79 to -0.53], p =.004).Conclusions: Subtle decline in specific cognitive domains may be present among people diagnosed with PD but without evidence to support a formal cognitive diagnosis. These results suggest the importance of early awareness of the potential for diminishing aspects of cognition in PD even among those without mild cognitive impairment or dementia.

    View details for DOI 10.1080/13803395.2021.1927995

    View details for PubMedID 34355669

  • Genetic Insights into Alzheimer's Disease. Annual review of pathology Latimer, C. S., Lucot, K. L., Keene, C. D., Cholerton, B., Montine, T. J. 2021; 16: 351–76

    Abstract

    Alzheimer's disease (AD) is a pervasive, relentlessly progressive neurodegenerative disorder that includes both hereditary and sporadic forms linked by common underlying neuropathologic changes and neuropsychological manifestations. While a clinical diagnosis is often made on the basis of initial memory dysfunction that progresses to involve multiple cognitive domains, definitive diagnosis requires autopsy examination of the brain to identify amyloid plaques and neurofibrillary degeneration. Over the past 100 years, there has been remarkable progress in our understanding of the underlying pathophysiologic processes, pathologic changes, and clinical phenotypes of AD, largely because genetic pathways that include but expand beyond amyloid processing have been uncovered. This review discusses the current state of understanding of the genetics of AD with a focus on how these advances are both shaping our understanding of the disease and informing novel avenues and approaches for development of potential therapeutic targets.

    View details for DOI 10.1146/annurev-pathmechdis-012419-032551

    View details for PubMedID 33497263

  • Relationship between Sensorimotor Inhibition and Mobility in Older Adults with and without Parkinson's Disease. The journals of gerontology. Series A, Biological sciences and medical sciences Martini, D. N., Morris, R., Madhyastha, T. M., Grabowski, T. J., Oakley, J., Hu, S., Zabetian, C. P., Edwards, K. L., Hiller, A., Chung, K., Ramsey, K., Lapidus, J. A., Cholerton, B., Montine, T. J., Quinn, J. F., Horak, F. B. 2020

    Abstract

    BACKGROUND: Reduced cortical sensorimotor inhibition is associated with mobility and cognitive impairments in people with Parkinson's disease (PD) and older adults (OAs). However, there is a lack of clarity regarding the relationships among sensorimotor, cognitive, and mobility impairments. The purpose of this study was to determine how cortical sensorimotor inhibition relates to impairments in mobility and cognition in people with PD and OAs.METHODS: Cortical sensorimotor inhibition was characterized with short-latency afferent inhibition (SAI) in 81 people with PD and 69 OAs. Six inertial sensors recorded single- and dual-task gait and postural sway characteristics during a two-minute walk and a one-minute quiet stance. Cognition was assessed across the memory, visuospatial, executive function, attention, and language domains.RESULTS: SAI was significantly impaired in the PD compared to the OA group. The PD group preformed significantly worse across all gait and postural sway tasks. In PD, SAI significantly correlated with single-task foot strike angle and stride length variability, sway area, and jerkiness of sway in the coronal and sagittal planes. In OAs, SAI significantly related to single-task gait speed and stride length, dual-task stride length, and immediate recall (memory domain). No relationship among mobility, cognition, and SAI was observed.CONCLUSIONS: Impaired SAI related to slower gait in OA and to increased gait variability and postural sway in people with PD, all of which have been shown to be related to increased fall risk.

    View details for DOI 10.1093/gerona/glaa300

    View details for PubMedID 33252618

  • White Matter Hyperintensities Related to Parkinson's Disease Executive Function. Movement disorders clinical practice Linortner, P., McDaniel, C., Shahid, M., Levine, T. F., Tian, L., Cholerton, B., Poston, K. L. 2020; 7 (6): 629-638

    Abstract

    People with Parkinson's disease (PD) can develop multidomain cognitive impairments; however, it is unclear whether different pathologies underlie domain-specific cognitive dysfunction.We investigated the contribution of vascular copathology severity and location, as measured by MRI white matter hyperintensities (WMHs), to domain-specific cognitive impairment in PD.We studied 85 PD (66.6 ± 9.2 years) and 18 control (65.9 ± 6.6) participants. Using the Fazekas scale for rating the severity of WMH, we subdivided PD into 14 PD-WMH+ and 71 PD-WMH-. Participants underwent global, executive, visuospatial, episodic memory, and language testing. We performed nonparametric permutation testing to create WMH probability maps based on PD-WMH group and cognitive test performance.The PD-WMH+ group showed worse global and executive cognitive performance than the PD-WMH- group. On individual tests, the PD-WMH+ group showed worse Montreal Cognitive Assessment (MoCA), Stroop, Symbol Digit Modalities Test (SDMT), and Digit Span scores. WMH probability maps showed that in the PD-WMH+ group, worse Stroop was associated with lesions centered around the corticospinal tract (CST), forceps major, inferior-fronto-occipital fasciculus, and superior longitudinal fasciculus; worse SDMT with lesions around the CST, forceps major, and posterior corona radiata; worse Digit Span with lesions around the posterior corona radiata; and worse MoCA with lesions around the CST.We found that WMH severity was associated with PD executive dysfunction, including worse attention, working memory, and processing speed. Disruption of key white matter tracts in proximity to vascular lesions could contribute to these specific cognitive impairments. Early treatment of vascular disease might mitigate some executive dysfunction in a subset of patients with PD.

    View details for DOI 10.1002/mdc3.12956

    View details for PubMedID 32775508

    View details for PubMedCentralID PMC7396844

  • Hallucinations and Development of Dementia in Parkinson's Disease. Journal of Parkinson's disease Gryc, W., Roberts, K. A., Zabetian, C. P., Weintraub, D., Trojanowski, J. Q., Quinn, J. F., Hiller, A. L., Chung, K. A., Poston, K. L., Yang, L., Hu, S., Edwards, K. L., Montine, T. J., Cholerton, B. A. 2020

    Abstract

    Neuropsychiatric symptoms are common in Parkinson's disease (PD). We investigated the relationship between neuropsychiatric symptoms and current and future diagnosis of PD dementia (PDD). Individuals with PD who had a study partner were enrolled (n = 696). Study partners were administered the Neuropsychiatric Inventory or Neuropsychiatric Inventory Questionnaire at baseline. Participants were assigned a cognitive diagnosis at baseline and follow up visits. Hallucinations were significantly associated with a diagnosis of PDD cross-sectionally (p < 0.001) and with shortened time to dementia longitudinally among initially nondemented participants (n = 444; p = 0.005). Screening for hallucinations may be useful for assessing risk of dementia in participants with PD.

    View details for DOI 10.3233/JPD-202116

    View details for PubMedID 32741842

  • White Matter Hyperintensities Related to Parkinson's Disease Executive Function MOVEMENT DISORDERS CLINICAL PRACTICE Linortner, P., McDaniel, C., Shahid, M., Levine, T. F., Tian, L., Cholerton, B., Poston, K. L. 2020

    View details for DOI 10.1002/mdc3.12956

    View details for Web of Science ID 000529623200001

  • APOE epsilon 4-related differences in visuospatial impairment in female Parkinson's Disease patients Rawls, A., Yang, L., Chung, K., Hiller, A., Espay, A., Revilla, F., Devoto, J., Goldman, J., Stebbins, G., Bernard, B., Wszolek, Z., Ross, O., Dickson, D., Rosenthal, L., Dawson, T., Albert, M., Factor, S., Weintraub, D., Trojanowski, J., Van Deerlin, V., Simuni, T., Lubbe, S., Mencacci, N., Hu, S., Leverenz, J., Quinn, J., Montine, T., Zabetian, C., Poston, K., Cholerton, B. LIPPINCOTT WILLIAMS & WILKINS. 2020
  • Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson's Disease MOVEMENT DISORDERS CLINICAL PRACTICE Cholerton, B., Poston, K. L., Tian, L., Quinn, J. F., Chung, K. A., Hiller, A. L., Hu, S., Specketer, K., Montine, T. J., Edwards, K. L., Zabetian, C. P. 2020; 7 (1): 61–69

    Abstract

    Cognitive dysfunction is common in Parkinson's disease (PD) and associated with reduced functional abilities and increased dependence. To date, however, little is known about the relationship between performance of instrumental activities of daily living (IADLs) and cognitive stages in PD, and there are conflicting reports as to whether declines in specific cognitive domains predict IADL impairment.Participants with PD were drawn from the Pacific Udall Center and included in the study if both participant and study partner IADL ratings and cognitive tests were completed (n = 192). Logistic regression analyses were performed to determine whether participant and/or study partner rating predicted mild cognitive impairment or dementia. Correlations are reported for the relationship between participant/study partner IADL reports as well as for specific cognitive tests.Although both participant and study partner ratings of IADL performance were associated with a diagnosis of PD with dementia, only participant self-rating of functional ability was significantly associated with a diagnosis of PD with mild cognitive impairment. Functional ability correlated most strongly with measures of processing speed, auditory working memory, and immediate verbal recall for both the participant and study partner ratings.For participants with PD in the early stages of cognitive decline, self-rating may be more sensitive to the impact of cognitive changes on IADL function than ratings made by a knowledgeable study partner. Changes in executive function, processing speed, and learning may indicate a higher likelihood of IADL impairment. Careful assessment of cognition and IADL performance is recommended to permit individualized interventions prior to significant disability.

    View details for DOI 10.1002/mdc3.12870

    View details for Web of Science ID 000507324100010

    View details for PubMedID 31970213

    View details for PubMedCentralID PMC6962683

  • Multivariate prediction of dementia in Parkinson's disease. NPJ Parkinson's disease Phongpreecha, T., Cholerton, B., Mata, I. F., Zabetian, C. P., Poston, K. L., Aghaeepour, N., Tian, L., Quinn, J. F., Chung, K. A., Hiller, A. L., Hu, S. C., Edwards, K. L., Montine, T. J. 2020; 6 (1): 20

    Abstract

    Cognitive impairment in Parkinson's disease (PD) is pervasive with potentially devastating effects. Identification of those at risk for cognitive decline is vital to identify and implement appropriate interventions. Robust multivariate approaches, including fixed-effect, mixed-effect, and multitask learning models, were used to study associations between biological, clinical, and cognitive factors and for predicting cognitive status longitudinally in a well-characterized prevalent PD cohort (n = 827). Age, disease duration, sex, and GBA status were the primary biological factors associated with cognitive status and progression to dementia. Specific cognitive tests were better predictors of subsequent cognitive status for cognitively unimpaired and dementia groups. However, these models could not accurately predict future mild cognitive impairment (PD-MCI). Data collected from a large PD cohort thus revealed the primary biological and cognitive factors associated with dementia, and provide clinicians with data to aid in the identification of risk for dementia. Sex differences and their potential relationship to genetic status are also discussed.

    View details for DOI 10.1038/s41531-020-00121-2

    View details for PubMedID 34429432

  • Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau. Brain : a journal of neurology Wilson, E. N., Swarovski, M. S., Linortner, P. n., Shahid, M. n., Zuckerman, A. J., Wang, Q. n., Channappa, D. n., Minhas, P. S., Mhatre, S. D., Plowey, E. D., Quinn, J. F., Zabetian, C. P., Tian, L. n., Longo, F. M., Cholerton, B. n., Montine, T. J., Poston, K. L., Andreasson, K. I. 2020

    Abstract

    Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease and affects 1% of the population above 60 years old. Although Parkinson's disease commonly manifests with motor symptoms, a majority of patients with Parkinson's disease subsequently develop cognitive impairment, which often progresses to dementia, a major cause of morbidity and disability. Parkinson's disease is characterized by α-synuclein accumulation that frequently associates with amyloid-β and tau fibrils, the hallmarks of Alzheimer's disease neuropathological changes; this co-occurrence suggests that onset of cognitive decline in Parkinson's disease may be associated with appearance of pathological amyloid-β and/or tau. Recent studies have highlighted the appearance of the soluble form of the triggering receptor expressed on myeloid cells 2 (sTREM2) receptor in CSF during development of Alzheimer's disease. Given the known association of microglial activation with advancing Parkinson's disease, we investigated whether CSF and/or plasma sTREM2 differed between CSF biomarker-defined Parkinson's disease participant subgroups. In this cross-sectional study, we examined 165 participants consisting of 17 cognitively normal elderly subjects, 45 patients with Parkinson's disease with no cognitive impairment, 86 with mild cognitive impairment, and 17 with dementia. Stratification of subjects by CSF amyloid-β and tau levels revealed that CSF sTREM2 concentrations were elevated in Parkinson's disease subgroups with a positive tau CSF biomarker signature, but not in Parkinson's disease subgroups with a positive CSF amyloid-β biomarker signature. These findings indicate that CSF sTREM2 could serve as a surrogate immune biomarker of neuronal injury in Parkinson's disease.

    View details for DOI 10.1093/brain/awaa021

    View details for PubMedID 32065223

  • White Matter Lesions in Mild Cognitive Impairment and Idiopathic Parkinson's Disease: Multimodal Advanced MRI and Cognitive Associations. Journal of neuroimaging : official journal of the American Society of Neuroimaging Rane, S. n., Owen, J. n., Hippe, D. S., Cholerton, B. n., Zabetian, C. P., Montine, T. n., Grabowski, T. J. 2020

    Abstract

    Cerebrovascular disease is a common comorbidity in older adults, typically assessed in terms of white matter hyperintensities (WMHs) on MRI. While it is well known that WMHs exacerbate cognitive symptoms, the exact relation of WMHs with cognitive performance and other degenerative diseases is unknown. Furthermore, based on location, WMHs are often classified into periventricular and deep WMHs and are believed to have different pathological origins. Whether the two types of WMHs influence cognition differently is unclear. Using regression models, we assessed the independent association of these two types of WMHs with cognitive performance in two separate studies focused on distinct degenerative diseases, early Alzheimer's (mild cognitive impairment), and Parkinson's disease. We further tested if the two types of WMHs were differentially associated with reduced cortical cerebral blood flow (CBF) as measured by arterial spin labeling and increased mean diffusivity (MD, a marker of tissue injury) as measured by diffusion imaging. Our approach revealed that both deep and periventricular WMHs were associated with poor performance on tests of global cognition (Montreal cognitive Assessment, MoCA), task processing (Trail making test), and category fluency in the study of mild cognitive impairment. They were associated with poor performance in global cognition (MoCA) and category fluency in the Parkinson's disease study. Of note, more associations were detected between cognitive performance and deep WMHs than between cognitive performance and periventricular WMHs. Mechanistically, both deep and periventricular WMHs were associated with increased MD. Both deep and periventricular WMHs were also associated with reduced CBF in the gray matter.

    View details for DOI 10.1111/jon.12778

    View details for PubMedID 32937003

  • Resting-State Cerebello-Cortical Dysfunction in Parkinson's Disease. Frontiers in neurology Palmer, W. C., Cholerton, B. A., Zabetian, C. P., Montine, T. J., Grabowski, T. J., Rane, S. 2020; 11: 594213

    Abstract

    Purpose: Recently, the cerebellum's role in Parkinson's disease (PD) has been highlighted. Therefore, this study sought to test the hypothesis that functional connectivity (FC) between cerebellar and cortical nodes of the resting-state networks differentiates PD patients from controls by scanning participants at rest using functional magnetic resonance imaging (fMRI) and investigating connectivity of the cerebellar nodes of the resting-state networks. Materials and Methods: Sixty-two PD participants off medication for at least 12 h and 33 normal controls (NCs) were scanned at rest using blood oxygenation level-dependent fMRI scans. Motor and cognitive functions were assessed with the Movement Disorder Society's Revision of the Unified Parkinson's Disease Rating Scale III and Montreal Cognitive Assessment, respectively. Connectivity was investigated with cerebellar seeds defined by Buckner's 7-network atlas. Results: PD participants had significant differences in FC when compared to NC participants. Most notably, PD patients had higher FC between cerebellar nodes of the somatomotor network (SMN) and the corresponding cortical nodes. Cognitive functioning was differentially associated with connectivity of the cerebellar SMN and dorsal attention network. Further, cerebellar connectivity of frontoparietal and default mode networks correlated with the severity of motor function. Conclusion: Our study demonstrates altered cerebello-cortical FC in PD, as well as an association of this FC with PD-related motor and cognitive disruptions, thus providing additional evidence for the cerebellum's role in PD.

    View details for DOI 10.3389/fneur.2020.594213

    View details for PubMedID 33584497

  • Multivariate prediction of dementia in Parkinson's disease. NPJ Parkinson's disease Phongpreecha, T. n., Cholerton, B. n., Mata, I. F., Zabetian, C. P., Poston, K. L., Aghaeepour, N. n., Tian, L. n., Quinn, J. F., Chung, K. A., Hiller, A. L., Hu, S. C., Edwards, K. L., Montine, T. J. 2020; 6: 20

    Abstract

    Cognitive impairment in Parkinson's disease (PD) is pervasive with potentially devastating effects. Identification of those at risk for cognitive decline is vital to identify and implement appropriate interventions. Robust multivariate approaches, including fixed-effect, mixed-effect, and multitask learning models, were used to study associations between biological, clinical, and cognitive factors and for predicting cognitive status longitudinally in a well-characterized prevalent PD cohort (n = 827). Age, disease duration, sex, and GBA status were the primary biological factors associated with cognitive status and progression to dementia. Specific cognitive tests were better predictors of subsequent cognitive status for cognitively unimpaired and dementia groups. However, these models could not accurately predict future mild cognitive impairment (PD-MCI). Data collected from a large PD cohort thus revealed the primary biological and cognitive factors associated with dementia, and provide clinicians with data to aid in the identification of risk for dementia. Sex differences and their potential relationship to genetic status are also discussed.

    View details for DOI 10.1038/s41531-020-00121-2

    View details for PubMedID 32885039

    View details for PubMedCentralID PMC7447766

  • Arterial spin labeling detects perfusion patterns related to motor symptoms in Parkinson's disease. Parkinsonism & related disorders Rane, S. n., Koh, N. n., Oakley, J. n., Caso, C. n., Zabetian, C. P., Cholerton, B. n., Montine, T. J., Grabowski, T. n. 2020; 76: 21–28

    Abstract

    Imaging neurovascular disturbances in Parkinson's disease (PD) is an excellent measure of disease severity. Indeed, a disease-specific regional pattern of abnormal metabolism has been identified using positron emission tomography. Only a handful of studies, however, have applied perfusion MRI to detect this disease pattern. Our goal was to replicate the evaluation of a PD-related perfusion pattern using scaled subprofile modeling/principal component analysis (SSM-PCA).We applied arterial spin labeling (ASL) MRI for this purpose. Uniquely, we assessed this pattern separately in PD individuals ON and OFF dopamine medications. We further compared the existence of these patterns and their strength in each individual with their Movement Disorder Society-Unified Parkinson's Disease Rating Scale motor (MDS-UPDRS) scores, cholinergic tone as indexed by short-term afferent inhibition (SAI), and other neuropsychiatric tests.We observed a PD-related perfusion pattern that was similar to previous studies. The patterns were observed in both ON and OFF states but only the pattern in the OFF condition could significantly (AUC=0.72) differentiate between PD and healthy subjects. In the ON condition, PD subjects were similar to controls from a CBF standpoint (AUC=0.45). The OFF pattern prominently included the posterior cingulate, precentral region, precuneus, and the subcallosal cortex. Individual principal components from the ON and OFF states were strongly associated with MDS-UPDRS scores, SAI amplitude and latency.Using ASL, our study identified patterns of abnormal perfusion in PD and were associated with disease symptoms.

    View details for DOI 10.1016/j.parkreldis.2020.05.014

    View details for PubMedID 32559629

  • Cognitive Correlates of MRI-defined Cerebral Vascular Injury and Atrophy in Elderly American Indians: The Strong Heart Study. Journal of the International Neuropsychological Society : JINS Suchy-Dicey, A., Shibata, D., Cholerton, B., Nelson, L., Calhoun, D., Ali, T., Montine, T. J., Longstreth, W. T., Buchwald, D., Verney, S. P. 2019: 1–13

    Abstract

    OBJECTIVE: American Indians experience substantial health disparities relative to the US population, including vascular brain aging. Poorer cognitive test performance has been associated with cranial magnetic resonance imaging findings in aging community populations, but no study has investigated these associations in elderly American Indians.METHODS: We examined 786 American Indians aged 64 years and older from the Cerebrovascular Disease and its Consequences in American Indians study (2010-2013). Cranial magnetic resonance images were scored for cortical and subcortical infarcts, hemorrhages, severity of white matter disease, sulcal widening, ventricle enlargement, and volumetric estimates for white matter hyperintensities (WMHs), hippocampus, and brain. Participants completed demographic, medical history, and neuropsychological assessments including testing for general cognitive functioning, verbal learning and memory, processing speed, phonemic fluency, and executive function.RESULTS: Processing speed was independently associated with the presence of any infarcts, white matter disease, and hippocampal and brain volumes, independent of socioeconomic, language, education, and clinical factors. Other significant associations included general cognitive functioning with hippocampal volume. Nonsignificant, marginal associations included general cognition with WMH and brain volume; verbal memory with hippocampal volume; verbal fluency and executive function with brain volume; and processing speed with ventricle enlargement.CONCLUSIONS: Brain-cognition associations found in this study of elderly American Indians are similar to those found in other racial/ethnic populations, with processing speed comprising an especially strong correlate of cerebrovascular disease. These findings may assist future efforts to define opportunities for disease prevention, to conduct research on diagnostic and normative standards, and to guide clinical evaluation of this underserved and overburdened population.

    View details for DOI 10.1017/S1355617719001073

    View details for PubMedID 31791442

  • The Associations Among Sociocultural Factors and Neuropsychological Functioning in Older American Indians: The Strong Heart Study NEUROPSYCHOLOGY Verney, S. P., Suchy-Dicey, A. M., Cholerton, B., Calhoun, D., Nelson, L., Montine, T. J., Ali, T., Longstreth, W. T., Buchwald, D. 2019; 33 (8): 1078–88

    Abstract

    Valid neuropsychological assessment is critical to the accurate diagnosis and effective treatment of diverse populations. American Indians and Alaska Natives experience substantial health disparities relative to the general U.S.Given the dearth of studies on neuropsychological health in this population, we aimed to characterize neuropsychological performance among older American Indians with respect to age, sex, education, income, and language use.From 2010 to 2014, we recruited 818 American Indians aged 60 and older from the Cerebrovascular Disease and Its Consequences in American Indians Study, who comprised all of the surviving members of a cardiovascular study (Strong Heart Study). This cohort from 11 tribes resided on or near their home reservations in three geographic regions (Northern Plains, Southern Plains, and Southwest). Using a cross-sectional design investigating potential vascular brain injury, we administered a brief, targeted neuropsychological and motor function assessments.Higher scores on neuropsychological tests were associated with younger age, female sex, more education, higher income, and less Native American language use. Similar associations were found for the motor tests, although men had higher scores on both motor function tests. After accounting for other sociocultural and health factors, age, sex, education, income, and Native American language use all had significant associations to the test scores.Our findings may be used to guide research and inform clinical practice. The development of future normative studies for older American Indians will be more culturally appropriate when sociocultural factors are included. (PsycINFO Database Record (c) 2019 APA, all rights reserved).

    View details for DOI 10.1037/neu0000574

    View details for Web of Science ID 000494295100005

    View details for PubMedID 31343235

  • Type 2 diabetes and later cognitive function in older American Indians: The Strong Heart Study INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Cholerton, B., Omidpanah, A., Verney, S. P., Nelson, L. A., Baker, L. D., Suchy-Dicey, A., Longstreth, W. T., Howard, B. V., Henderson, J. A., Montine, T. J., Buchwald, D. 2019; 34 (7): 1050–57

    View details for DOI 10.1002/gps.5108

    View details for Web of Science ID 000471829900017

  • An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF A beta 42 and an APOE epsilon 4 allele NEUROBIOLOGY OF DISEASE Shahid, M., Kim, J., Leaver, K., Hendershott, T., Zhu, D., Cholerton, B., Henderson, V. W., Tian, L., Poston, K. L. 2019; 127: 278–86
  • Type 2 diabetes and later cognitive function in older American Indians: The Strong Heart Study. International journal of geriatric psychiatry Cholerton, B., Omidpanah, A., Verney, S. P., Nelson, L. A., Baker, L. D., Suchy-Dicey, A., Longstreth, W. T., Howard, B. V., Henderson, J. A., Montine, T. J., Buchwald, D. 2019

    Abstract

    OBJECTIVES: Insulin resistance is a substantial health issue for American Indians, with type 2 diabetes overrepresented in this population as compared to non-Hispanic whites. Insulin resistance and its related conditions in turn increase risk for dementia and cognitive impairment. The aim of the current study was to determine whether type 2 diabetes and insulin resistance at midlife was associated with later life cognitive testing in a large sample of older American Indians, aged 65 and over.METHODS: American Indian participants who underwent both fasting blood draw as part of the Strong Heart Study and had subsequent cognitive testing as part of the later adjunct Cerebrovascular Disease and its Consequences in American Indians study were included (n=790). Regression models examined type 2 diabetes and impaired fasting glucose and subsequent cognitive test performance as part of a longitudinal study design. The relationship between a continuous measure of insulin resistance and later cognitive test performance was assessed using generalized estimating equations.RESULTS: Controlling for demographic and clinical factors, verbal fluency and processing speed/working memory were significantly negatively associated with having type 2 diabetes and with insulin resistance, but not with impaired fasting glucose.CONCLUSION: In this sample of American Indians, type 2 diabetes at midlife was associated with subsequent lower performance on measures of executive function. These results may have important implications for future implementation of diagnostic and intervention services in this population.

    View details for PubMedID 30924200

  • Cognitive Performance in Parkinson's Disease in the Brain Health Registry. Journal of Alzheimer's disease : JAD Cholerton, B., Weiner, M. W., Nosheny, R. L., Poston, K. L., Scott Mackin, R., Tian, L., Ashford, J. W., Montine, T. J. 2019

    Abstract

    The study of cognition in Parkinson's disease (PD) traditionally requires exhaustive recruitment strategies. The current study examines data collected by the Brain Health Registry (BHR) to determine whether ongoing efforts to improve the recruitment base for therapeutic trials in Alzheimer's disease may be similarly effective for PD research, and whether online cognitive measurements can discriminate between participants who do and do not report a PD diagnosis. Participants enrolled in the BHR (age ≥50) with self-reported PD data and online cognitive testing available were included (n = 11,813). Associations between baseline cognitive variables and diagnostic group were analyzed using logistic regression. Linear mixed effects models were used to analyze longitudinal data. A total of 634 participants reported PD diagnosis at baseline with no self-reported cognitive impairment and completed cognitive testing. Measures of visual learning and memory, processing speed, attention, and working memory discriminated between self-reported PD and non-PD participants after correcting for multiple comparisons (p values <  0.006). Scores on all cognitive tests improved over time in PD and controls with the exception of processing speed, which remained stable in participants with PD while improving in those without. We demonstrate that a novel online approach to recruitment and longitudinal follow-up of study participants is effective for those with self-reported PD, and that significant differences exist between those with and without a reported diagnosis of PD on computerized cognitive measures. These results have important implications for recruitment of participants with PD into targeted therapeutic trials or large-scale genetic and cognitive studies.

    View details for PubMedID 30909225

  • Using Varying Diagnostic Criteria to Examine Mild Cognitive Impairment Prevalence and Predict Dementia Incidence in a Community-Based Sample. Journal of Alzheimer's disease : JAD Robertson, K., Larson, E. B., Crane, P. K., Cholerton, B., Craft, S., McCormick, W. C., McCurry, S. M., Bowen, J. D., Baker, L. D., Trittschuh, E. H. 2019

    Abstract

    Lack of a unitary operational definition of mild cognitive impairment (MCI) has resulted in mixed prevalence rates and unclear predictive validity regarding conversion to dementia and likelihood of reversion. We examined 1,721 nondemented participants aged 65 and older from the Adult Changes in Thought (ACT) community-based cohort. Participants were followed longitudinally through biennial visits (average years assessed = 5.38). Categorization of MCI was based on: 1) deviation of neuropsychological test scores from a benchmark based on either standard or individualized expectations of a participant's mean premorbid cognitive ability, and 2) cutoff for impairment (1.0 versus 1.5 standard deviations [sd] below benchmark). MCI prevalence ranged from 56-92%; using individualized benchmarks and less stringent cutoffs produced higher rates. During follow-up, 17% of the cohort developed dementia. Examination of sensitivity, specificity, and predictive validity revealed that the criterion of 1.5 sd from the standardized benchmark was optimal, but still had limited predictive validity. Participants meeting this criterion at their first visit were three times more likely to develop dementia and this increased to seven times if participants had this diagnosis at the second timepoint as well. Those who did not have an MCI diagnosis at their first visit, but did at their second, had a significant increase of risk (but to a lesser extent than those diagnosed at both visits), while those who had an MCI diagnosis at their first visit, but not their second, did not have a significantly increased risk. These results highlight how assessing MCI stability greatly improves prediction of risk.

    View details for PubMedID 30909213

  • Concepts for brain aging: resistance, resilience, reserve, and compensation. Alzheimer's research & therapy Montine, T. J., Cholerton, B. A., Corrada, M. M., Edland, S. D., Flanagan, M. E., Hemmy, L. S., Kawas, C. H., White, L. R. 2019; 11 (1): 22

    Abstract

    A primary goal of research in cognitive impairment and dementia is to understand how some individuals retain sufficient cognitive function for a fulfilling life while many others are robbed of their independence, sometimes their essence, in the last years and decades of life. In this commentary, we propose operational definitions of the types of factors that may help individuals retain cognitive function with aging. We propose operational definitions of resistance, resilience, reserve, with an eye toward how these may be measured and interpreted, and how they may enable research aimed at prevention. With operational definitions and quantification of resistance, resilience, and reserve, a focused analytic search for their determinants and correlates can be undertaken. This approach, essentially a search to identify protective risk factors and their mechanisms, represents a relatively unexplored pathway toward the identification of candidate preventive interventions.

    View details for PubMedID 30857563

  • Concepts for brain aging: resistance, resilience, reserve, and compensation ALZHEIMERS RESEARCH & THERAPY Montine, T. J., Cholerton, B. A., Corrada, M. M., Edland, S. D., Flanagan, M. E., Hemmy, L. S., Kawas, C. H., White, L. R. 2019; 11
  • An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF ASS42 and an APOE epsilon4 allele. Neurobiology of disease Shahid, M., Kim, J., Leaver, K., Hendershott, T., Zhu, D., Cholerton, B., Henderson, V. W., Tian, L., Poston, K. L. 2019

    Abstract

    OBJECTIVE: Low concentrations of cerebrospinal fluid (CSF) amyloid-beta (Abeta-42) are associated with increased risk of cognitive decline in Parkinson's disease (PD). We sought to determine whether APOE genotype modifies the rate of cognitive decline in PD patients with low CSF Abeta-42 compared to patients with normal levels.METHODS: The Parkinson's Progression Markers Initiative is a longitudinal, ongoing study of de novo PD participants, which includes APOE genotyping, CSF Abeta-42 determinations, and neuropsychological assessments. We used linear mixed effects models in three PD groups (PD participants with low CSF Abeta at baseline, PD participants with normal CSF Abeta, and both groups combined). Having at least one copy of the APOE ɛ4 allele, time, and the interaction of APOE ɛ4 and time were predictor variables for cognitive change, adjusting for age, gender and education.RESULTS: 423 de novo PD participants were followed up to 5 years with annual cognitive assessments. 103 participants had low baseline CSF Abeta-42 (39 APOE epsilon4+, 64 APOE epsilon4-). Compared to participants with normal CSF Abeta-42, those with low CSF Abeta-42 declined faster on most cognitive tests. Within the low CSF Abeta-42 group, APOE epsilon4+ participants had faster rates of decline on the Montreal Cognitive Assessment (primary outcome; 0.57 points annual decline, p = .005; 5-year standardized change of 1.2) and the Symbol Digit Modalities Test (1.4 points annual decline, p = .002; 5-year standardized change of 0.72).DISCUSSION: PD patients with low CSF Abeta-42 and APOE epsilon4+ showed a higher rate of cognitive decline early in the disease. Tests of global cognition (Montreal Cognitive Assessment) and processing speed (Symbol Digit Modalities Test) were the most sensitive to early cognitive decline. Results suggest that CSF Abeta-42 and APOE epsilon4 might interact to promote early cognitive changes in PD patients.

    View details for PubMedID 30826425

  • Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society Hendershott, T. R., Zhu, D., Llanes, S., Zabetian, C. P., Quinn, J., Edwards, K. L., Leverenz, J. B., Montine, T., Cholerton, B., Poston, K. L. 2019; 34 (2): 285–91

    Abstract

    BACKGROUND: Clinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD.METHODS: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 were administered to training and validation cohorts. Cutoff scores were determined within the training cohort (n = 85) to optimize sensitivity and specificity for cognitive impairment and were applied to an independent validation cohort (n = 521).RESULTS: The Montreal Cognitive Assessment was consistently sensitive across training and validation cohorts (90.0% and 80.3%, respectively), whereas the Mattis Dementia Rating Scale-2 was not (87.5% and 60.3%, respectively). In individual domains, the Montreal Cognitive Assessment remained sensitive to memory and visuospatial impairments (91.9% and 87.8%, respectively), whereas the Mattis Dementia Rating Scale-2 was sensitive to executive impairments (86.2%).CONCLUSION: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 demonstrated individual strengths. Future work should focus on developing domain-specific cognitive screening tools for PD. © 2018 International Parkinson and Movement Disorder Society.

    View details for PubMedID 30776152

  • Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease MOVEMENT DISORDERS Hendershott, T. R., Zhu, D., Llanes, S., Zabetian, C. P., Quinn, J., Edwards, K. L., Leverenz, J. B., Montine, T., Cholerton, B., Poston, K. L. 2019; 34 (2): 285–91

    View details for DOI 10.1002/mds.27575

    View details for Web of Science ID 000458973000016

  • Cognitive Performance in Parkinson's Disease in the Brain Health Registry JOURNAL OF ALZHEIMERS DISEASE Cholerton, B., Weiner, M. W., Nosheny, R. L., Poston, K. L., Mackin, R., Tian, L., Ashford, J., Montine, T. J. 2019; 68 (3): 1029–38

    View details for DOI 10.3233/JAD-181009

    View details for Web of Science ID 000464031500013

  • Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures. Clinical parkinsonism & related disorders Kim, H. M., Nazor, C., Zabetian, C. P., Quinn, J. F., Chung, K. A., Hiller, A. L., Hu, S., Leverenz, J. B., Montine, T. J., Edwards, K. L., Cholerton, B. 2019; 1: 91–97

    Abstract

    Introduction: Cognitive impairment is a common complication of Parkinson's disease (PD) and identifying risk factors for progression to Parkinson's disease dementia (PDD) is important. However, little research has been done comparing the utility of commonly used cognitive screening tests in predicting cognitive progression in PD.Methods: We retrospectively reviewed data from patients with PD enrolled in the Pacific Udall Center who had baseline and longitudinal neuropsychological and global cognitive screening tests. The diagnostic accuracies of 3 common screening tests were compared: Montreal Cognitive Assessment (MoCA), Mattis Dementia Rating Scale (DRS-2), and Mini Mental Status Examination (MMSE). Cognitive diagnoses of PD with mild cognitive impairment (PD-MCI) and PDD were based on full neuropsychological testing and established Movement Disorder Society criteria. Logistic regression and Cox proportional hazards regression models were used to examine predictors of cognitive decline.Results: Four hundred seventy patients for whom scores on all 3 screening tests were available from the same assessment were included in a cross-sectional analysis. The MoCA demonstrated the best overall diagnostic accuracy for PD-MCI (AUC= 0.79, sensitivity= 76.4%) and for PDD (AUC= 0.89, sensitivity= 81.0%) compared to the DRS-2 and MMSE. A longitudinal analysis was performed on the subset of patients (316/470; 67.2%) who were nondemented at baseline and had undergone two or more assessments. After controlling for covariates, the MoCA was the only test associated with progression to PDD (OR= 1.27 95% CI 1.1 - 1.5, p=0.001) and faster time to dementia (HR = 1.3, 95% CI 1.1 - 1.4, p<0.0001).Conclusions: This study provides additional support for the use of the MoCA as a primary screening tool for cognitive impairment in PD and is the first to show that the MoCA is a predictor of conversion to PDD.

    View details for DOI 10.1016/j.prdoa.2019.08.006

    View details for PubMedID 32368733

  • Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease. Parkinsonism & related disorders Morris, R. n., Martini, D. N., Smulders, K. n., Kelly, V. E., Zabetian, C. P., Poston, K. n., Hiller, A. n., Chung, K. A., Yang, L. n., Hu, S. C., Edwards, K. L., Cholerton, B. n., Grabowski, T. J., Montine, T. J., Quinn, J. F., Horak, F. n. 2019; 69: 104–10

    Abstract

    Gait and balance impairments are cardinal features of Parkinson's disease (PD) that require cognitive input. However, the extent to which specific gait and balance characteristics relate to cognition in PD is unclear. In addition, independent models of gait and balance have not been developed from the same cohort. We aimed to i) develop models of gait and balance in a large PD cohort and ii) determine which gait and balance characteristics best related to cognition.One hundred and ninety-eight people with PD were recruited to the Pacific Udall Center. Using six inertial sensors (APDM, Inc.), comprehensive gait measurements were collected over a 2-min continuous walk and comprehensive static balance measures were collected during a 60-second standing task. Six domains of cognition were assessed: global cognition, attention, executive function, language, memory, and visuospatial function. Correlations and hierarchical linear regression determined independent associations.Principal components analysis identified a gait model containing four domains accounting for 80.1% of total variance: pace/turning, rhythm, variability, and trunk. The balance model contained four independent domains accounting for 84.5% of total variance: sway area/jerkiness, sway velocity, sway frequency anteroposterior, and sway frequency mediolateral. Gait domains of pace/turning and variability were strongly associated with attention and executive function. Sway area and jerkiness of balance associated with attention and visuospatial function.Gait and balance characteristics were associated with specific types of cognition. The specific relationships between gait or balance with cognitive functions suggests shared cerebral cortical circuitry for mobility and cognitive functions.

    View details for DOI 10.1016/j.parkreldis.2019.06.014

    View details for PubMedID 31731260

  • Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinson's disease. Journal of clinical and experimental neuropsychology Specketer, K. n., Zabetian, C. P., Edwards, K. L., Tian, L. n., Quinn, J. F., Peterson-Hiller, A. L., Chung, K. A., Hu, S. C., Montine, T. J., Cholerton, B. A. 2019: 1–11

    Abstract

    Introduction: Cognitive impairment is a common symptom of Parkinson's disease (PD) associated with reduced quality of life and a more severe disease state. Previous research has shown an association between visuospatial dysfunction and worse disease course; however, it is not clear whether this is separable from executive dysfunction and/or dementia. This study sought to determine whether distinct cognitive factors could be measured in a large PD cohort, and if those factors were differentially associated with other PD-related features, specifically to provide insight into visuospatial dysfunction. Methods: Non-demented participants with PD from the Pacific Udall Center were enrolled (n = 197). Co-participants (n = 104) completed questionnaires when available. Principal components factor analysis (PCFA) was utilized to group the neuropsychological test scores into independent factors by considering those with big factor loading (≥.40). Linear and logistic regression analyses were performed to examine the relationship between the cognitive factors identified in the PCFA and other clinical features of PD. Results: Six factors were extracted from the PCFA: 1) executive/processing speed, 2) visual learning & memory/visuospatial, 3) auditory working memory, 4) contextual verbal memory, 5) semantic learning & memory, and 6) visuospatial. Motor severity (p = 0.001), mood (p < 0.001), and performance on activities of daily living scores (informant: p < 0.001, patient: p = 0.009) were primarily associated with frontal and executive factors. General sleep disturbance (p < 0.006) and hallucinations (p = 0.002) were primarily associated with visuospatial functioning and visual learning/memory. Conclusions: Motor symptoms, mood, and performance on activities of daily living were primarily associated with frontal/executive factors. Sleep disturbance and hallucinations were associated with visuospatial functioning and visual learning/memory only, over and above executive functioning and regardless of cognitive disease severity. These findings support that visuospatial function in PD may indicate a more severe disease course, and that symptom management should be guided accordingly.

    View details for DOI 10.1080/13803395.2019.1623180

    View details for PubMedID 31177941

  • Using Varying Diagnostic Criteria to Examine Mild Cognitive Impairment Prevalence and Predict Dementia Incidence in a Community-Based Sample JOURNAL OF ALZHEIMERS DISEASE Robertson, K., Larson, E. B., Crane, P. K., Cholerton, B., Craft, S., McCormick, W. C., McCurry, S. M., Bowen, J. D., Baker, L. D., Trittschuh, E. H. 2019; 68 (4): 1439–51

    View details for DOI 10.3233/JAD-180746

    View details for Web of Science ID 000465612500011

  • TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study. Journal of Alzheimer's disease : JAD Flanagan, M. E., Cholerton, B., Latimer, C. S., Hemmy, L. S., Edland, S. D., Montine, K. S., White, L. R., Montine, T. J. 2018

    Abstract

    Transactive response binding protein-43 (TDP-43) cytoplasmic neuronal and glial aggregates (pathologic TDP-43) have been described in multiple brain diseases. We describe the associations between neuropathologically confirmed TDP-43 and cognition in two population-based cohorts: the Nun Study (NS) and the Honolulu-Asia Aging Study (HAAS). In the HAAS, there was a significant association between hippocampal sclerosis (HS) and TDP-43 (OR = 11.04, p <  0.0001, 95% CI 3.57-34.13). In the NS, there were significant associations between TDP-43 and HS (OR = 16.44, p >  0.001 95%, CI 7.10-38.00) and Alzheimer's disease (AD) severity (OR = 1.74, p = 0.009, 95% CI 1.15-2.64). When cognitive scores were added to the model, HS remained significant but the other variables were not. When HS was removed from the model, the overall model remained significant and the associations between cognitive performance and TDP-43 (OR = 2.11, p = 0.022, 95% CI 1.11-4.02) were significant. In the NS, there was a significant association between cognitive performance and TDP-43 (OR 1.94 p = 0.005, 95% CI 1.22-3.09) (HS remained significant, but AD did not). When HS was removed from the model, only CERAD was significant (OR = 2.43 p <  0.001, 95% CI 1.58-3.74). These results support a consistent association between pathologic TDP-43, HS, and the development of cognitive impairment in two large studies of brain aging, while the relationship between AD pathology and TDP-43 may vary according to cohort-specific features.

    View details for PubMedID 30452409

  • Associations of APOE in the Honolulu Asia Aging Study Flanagan, M., Edland, S., Hemmy, L., Cholerton, B., Montine, T., White, L. OXFORD UNIV PRESS INC. 2018: 498
  • Neuropathologic Associations of APOE in the Nun Study Flanagan, M., Edland, S., Hemmy, L., Meints, J., Cholerton, B., Lim, K., Montine, T., White, L. OXFORD UNIV PRESS INC. 2018: 499
  • Quantitative cerebrovascular pathology in a community-based cohort of older adults NEUROBIOLOGY OF AGING Rane, S., Koh, N., Boord, P., Madhyastha, T., Askren, M. K., Jayadev, S., Cholerton, B., Larson, E., Grabowski, T. J. 2018; 65: 77–85

    Abstract

    Cerebrovascular disease, especially small vessel pathology, is the leading comorbidity in degenerative disorders. We applied arterial spin labeling and cerebrovascular reserve (CVR) imaging to quantify small vessel disease and study its effect on cognitive symptoms in nondemented older adults from a community-based cohort. We evaluated baseline cerebral blood flow (CBF) using arterial spin labeling and percent signal change as a marker of CVR using blood-oxygen level-dependent imaging following a breath-hold stimulus. Measurements were performed in and near white matter hyperintensities, which are currently the standard to assess severity of vascular pathology. We show that similar to other studies (1) CBF and CVR are markedly reduced in the hyperintensities as well as in the tissue surrounding them, indicating susceptibility to infarction; (2) low CBF and CVR are significantly correlated with poor cognitive performance; and (3) in addition, compared to a 58.4% reduction in CBF, larger exhaustion (79.3%) of CVR was observed in the hyperintensities with a faster, nonlinear rate of decline. We conclude that CVR may be a more sensitive biomarker of small vessel disease than CBF.

    View details for PubMedID 29452984

    View details for PubMedCentralID PMC5871567

  • Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease PARKINSONISM & RELATED DISORDERS Cholerton, B., Johnson, C. O., Fish, B., Quinn, J. F., Chung, K. A., Peterson-Hiller, A. L., Rosenthal, L. S., Dawson, T. M., Albert, M. S., Hu, S., Mata, I. F., Leverenz, J. B., Poston, K. L., Montine, T. J., Zabetian, C. P., Edwards, K. L. 2018; 50: 29–36
  • Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. Parkinsonism & related disorders Cholerton, B., Johnson, C. O., Fish, B., Quinn, J. F., Chung, K. A., Peterson-Hiller, A. L., Rosenthal, L. S., Dawson, T. M., Albert, M. S., Hu, S., Mata, I. F., Leverenz, J. B., Poston, K. L., Montine, T. J., Zabetian, C. P., Edwards, K. L. 2018

    Abstract

    INTRODUCTION: Identification of factors associated with progression of cognitive symptoms in Parkinson's disease (PD) is important for treatment planning, clinical care, and design of future clinical trials. The current study sought to identify whether prediction of cognitive progression is aided by examining baseline cognitive features, and whether this differs according to stage of cognitive disease.METHODS: Participants with PD in the Pacific Udall Center Clinical Consortium who had longitudinal data available and were nondemented at baseline were included in the study (n = 418). Logistic and Cox regression models were utilized to examine the relationship between cognitive, demographic, and clinical variables with risk and time to progression from no cognitive impairment to mild cognitive impairment (PD-MCI) or dementia (PDD), and from PD-MCI to PDD.RESULTS: Processing speed (OR = 1.05, p = 0.009) and working memory (OR = 1.01, p = 0.03) were associated with conversion to PDD among those with PD-MCI at baseline, over and above demographic variables. Conversely, the primary predictive factor in the transition from no cognitive impairment to PD-MCI or PDD was male sex (OR = 4.47, p = 0.004), and males progressed more rapidly than females (p = 0.01). Further, among females with shorter disease duration, progression was slower than for their male counterparts, and poor baseline performance on semantic verbal fluency was associated with shorter time to cognitive impairment in females but not in males.CONCLUSIONS: This study provides evidence for sex differences in the progression to cognitive impairment in PD, while specific cognitive features become more important indicators of progression with impending conversion to PDD.

    View details for PubMedID 29478836

  • Associations between Use of Specific Analgesics and Concentrations of Amyloid-beta 42 or Phospho-Tau in Regions of Human Cerebral Cortex JOURNAL OF ALZHEIMERS DISEASE Flanagan, M. E., Larson, E. B., Walker, R. L., Keene, C., Postupna, N., Cholerton, B., Sonnen, J. A., Dublin, S., Crane, P. K., Montine, T. J. 2018; 61 (2): 653–62

    Abstract

    Analgesics are commonly used by older adults, raising the question of whether their use might contribute to dementia risk and neuropathologic changes of Alzheimer's disease (AD). The Adult Changes in Thought (ACT) study is a population-based study of brain aging and incident dementia among people 65 years or older who are community dwelling and not demented at entry. Amyloid-β (Aβ)42 and phospho-tau were quantified using Histelide in regions of cerebral cortex from 420 brain autopsies. Total standard daily doses of prescription opioid and non-aspirin nonsteroidal anti-inflammatory drug (NSAID) exposure during a defined 10-year exposure window were identified using automated pharmacy dispensing data and used to classify people as having no/low, intermediate, or high exposure. People with high NSAID exposure had significantly greater Aβ42 concentration in middle frontal gyrus and superior and middle temporal gyri, but not inferior parietal lobule; no Aβ42 regional concentration was associated with prescription opioid usage. People with high opioid usage had significantly greater concentration of phospho-tau in middle frontal gyrus than people with little-to-no opioid usage. Consistent with our previous studies, findings suggest that high levels of NSAID use in older individuals may promote Aβ42 accumulation in cerebral cortex.

    View details for PubMedID 29226863

    View details for PubMedCentralID PMC5745256

  • TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study JOURNAL OF ALZHEIMERS DISEASE Flanagan, M. E., Cholerton, B., Latimer, C. S., Hemmy, L. S., Edland, S. D., Montine, K. S., White, L. R., Montine, T. J. 2018; 66 (4): 1549–58

    View details for DOI 10.3233/JAD-180162

    View details for Web of Science ID 000457776400021

  • Homocysteine and cognitive function in Parkinson's disease PARKINSONISM & RELATED DISORDERS Licking, N., Murchison, C., Cholerton, B., Zabetian, C. P., Hu, S., Montine, T. J., Peterson-Hiller, A. L., Chung, K. A., Edwards, K., Leverenz, J. B., Quinn, J. F. 2017; 44: 1–5

    Abstract

    Increased plasma homocysteine (HC) is a risk factor for dementia in the general population. Levodopa therapy causes increased plasma HC, but it remains unclear whether elevated plasma HC is associated with cognitive impairment in Parkinson's disease (PD).The study population includes all participants in the Pacific Northwest Udall Center (PANUC) Clinical cohort at the time of the study, consisting of 294 individuals with PD who had a standardized neuropsychological assessment and plasma collection for HC measurement. We tested the hypothesis that elevated plasma HC is inversely related to cognitive function in patients with PD.As expected, plasma HC was positively associated with age, disease duration, disease severity, and levodopa usage, while cognitive function was associated with age, education, gender, and APOE genotype, so subsequent analyses controlled for these covariates. When plasma HC was dichotomized as normal (<14 μmol/L) or elevated (≥14 μmol/L), subjects with hyper-homocysteinemia had lower scores on Digit Symbol (p = 0.031), Hopkins Verbal Learning Task (HVLT) Delayed Recall (p = 0.004), and semantic verbal fluency (p = 0.049). When examined as a continuous variable, plasma HC was inversely associated with HVLT Delayed Recall (p = 0.009)) and semantic verbal fluency (p = 0.004), but was not significantly related to Digit symbol, Trail-making test, Judgment of Line Orientation, phonemic verbal fluency, MMSE, or MOCA. When analysis was restricted to non-demented subjects (n = 231), the findings were unchanged.We conclude that plasma HC is significantly associated with some aspects of cognitive function in PD, and may represent a treatable risk factor for cognitive decline in PD.

    View details for PubMedID 28807493

    View details for PubMedCentralID PMC5858907

  • Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease NEUROBIOLOGY OF AGING Mata, I. F., Johnson, C. O., Leverenz, J. B., Weintraub, D., Trojanowski, J. Q., Van Deerlin, V. M., Ritz, B., Rausch, R., Factor, S. A., Wood-Siverio, C., Quinn, J. F., Chung, K. A., Peterson-Hiller, A. L., Espay, A. J., Revilla, F. J., Devoto, J., Yearout, D., Hu, S., Cholerton, B. A., Montine, T. J., Edwards, K. L., Zabetian, C. P. 2017; 56: 211.e1–211.e7

    Abstract

    Cognitive impairment is a common and disabling problem in Parkinson's disease (PD). Identification of genetic variants that influence the presence or severity of cognitive deficits in PD might provide a clearer understanding of the pathophysiology underlying this important nonmotor feature. We genotyped 1105 PD patients from the PD Cognitive Genetics Consortium for 249,336 variants using the NeuroX array. Participants underwent assessments of learning and memory (Hopkins Verbal Learning Test-Revised [HVLT-R]), working memory/executive function (Letter-Number Sequencing and Trail Making Test [TMT] A and B), language processing (semantic and phonemic verbal fluency), visuospatial abilities (Benton Judgment of Line Orientation [JoLO]), and global cognitive function (Montreal Cognitive Assessment). For common variants, we used linear regression to test for association between genotype and cognitive performance with adjustment for important covariates. Rare variants were analyzed using the optimal unified sequence kernel association test. The significance threshold was defined as a false discovery rate-corrected p-value (PFDR) of 0.05. Eighteen common variants in 13 genomic regions exceeded the significance threshold for one of the cognitive tests. These included GBA rs2230288 (E326K; PFDR = 2.7 × 10-4) for JoLO, PARP4 rs9318600 (PFDR = 0.006), and rs9581094 (PFDR = 0.006) for HVLT-R total recall, and MTCL1 rs34877994 (PFDR = 0.01) for TMT B-A. Analysis of rare variants did not yield any significant gene regions. We have conducted the first large-scale PD cognitive genetics analysis and nominated several new putative susceptibility genes for cognitive impairment in PD. These results will require replication in independent PD cohorts.

    View details for DOI 10.1016/j.neurobiolaging.2017.04.009

    View details for Web of Science ID 000405463300022

    View details for PubMedID 28526295

    View details for PubMedCentralID PMC5536182

  • TDP43 associations in the Nun Study and Honolulu Asian Aging Study Flanagan, M., Hemmy, L., Cholerton, B., Edland, S., Montine, K., White, L., Montine, T. OXFORD UNIV PRESS INC. 2017: 531
  • Total Brain and Hippocampal Volumes and Cognition in Older American Indians: The Strong Heart Study ALZHEIMER DISEASE & ASSOCIATED DISORDERS Cholerton, B., Omidpanah, A., Madhyastha, T. M., Grabowski, T. J., Suchy-Dicey, A. M., Shibata, D. K., Nelson, L. A., Verney, S. P., Howard, B. V., Longstreth, W. T., Montine, T. J., Buchwald, D. 2017; 31 (2): 94-100

    Abstract

    Estimates of hippocampal volume by magnetic resonance imaging have clinical and cognitive correlations and can assist in early Alzheimer disease diagnosis. However, little is known about the relationship between global or regional brain volumes and cognitive test performance in American Indians.American Indian participants (N=698; median age, 72 y) recruited for the Cerebrovascular Disease and its Consequences in American Indians study, an ancillary study of the Strong Heart Study cohort, were enrolled. Linear regression models assessed the relationship between magnetic resonance imaging brain volumes (total brain and hippocampi) and cognitive measures of verbal learning and recall, processing speed, verbal fluency, and global cognition.After controlling for demographic and clinical factors, all volumetric measurements were positively associated with processing speed. Total brain volume was also positively associated with verbal learning, but not with verbal recall. Conversely, left hippocampal volume was associated with both verbal learning and recall. The relationship between hippocampal volume and recall performance was more pronounced among those with lower scores on a global cognitive measure. Controlling for APOE ε4 did not substantively affect the associations.These results support further investigation into the relationship between structural Alzheimer disease biomarkers, cognition, genetics, and vascular risk factors in aging American Indians.

    View details for DOI 10.1097/WAD.0000000000000203

    View details for Web of Science ID 000401899300002

    View details for PubMedID 28538087

  • Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial JOURNAL OF ALZHEIMERS DISEASE Craft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., Jung, Y., Maldjian, J., Whitlow, C., Friedman, S. 2017; 57 (4): 1325-1334

    Abstract

    Long acting insulin detemir administered intranasally for three weeks enhanced memory for adults with Alzheimer's disease dementia (AD) or amnestic mild cognitive impairment (MCI). The investigation of longer-term administration is necessary to determine whether benefits persist, whether they are similar to benefits provided by regular insulin, and whether either form of insulin therapy affects AD biomarkers.The present study aimed to determine whether four months of treatment with intranasal insulin detemir or regular insulin improves cognition, daily functioning, and AD biomarkers for adults with MCI or AD.This randomized, double-blind, placebo-controlled trial included an intent-to-treat sample consisting of 36 adults diagnosed with MCI or mild to moderate AD. Participants received placebo (n = 12), 40 IU of insulin detemir (n = 12), or 40 IU of regular insulin (n = 12) daily for four months, administered with a nasal delivery device. A cognitive battery was administered at baseline and after two and four months of treatment. MRI was administered for all participants and lumbar puncture for a subset (n = 20) at baseline and four months. The primary outcome was change from baseline to four months on a memory composite (sum of Z scores for delayed list and story recall). Secondary outcomes included: global cognition (Alzheimer's Disease Assessment Scale-Cognition), daily functioning (Dementia Severity Rating Scale), MRI volume changes in AD-related regions of interest, and cerebrospinal fluid AD markers.The regular insulin treated group had better memory after two and four months compared with placebo (p < 0.03). No significant effects were observed for the detemir-assigned group compared with the placebo group, or for daily functioning for either group. Regular insulin treatment was associated with preserved volume on MRI. Regular insulin treatment was also associated with reduction in the tau-P181/Aβ42 ratio.Future research is warranted to examine the mechanistic basis of treatment differences, and to further assess the efficacy and safety of intranasal insulin.

    View details for DOI 10.3233/JAD-161256

    View details for Web of Science ID 000399933800028

    View details for PubMedID 28372335

  • Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach. Diabetes spectrum : a publication of the American Diabetes Association Cholerton, B., Baker, L. D., Montine, T. J., Craft, S. 2016; 29 (4): 210-219

    Abstract

    IN BRIEF There has been a concurrent dramatic rise in type 2 diabetes and dementia in the United States, and type 2 diabetes shares common genetic and environmental risk factors and underlying pathology with both vascular and Alzheimer's dementias. Given the ability to identify this at-risk population and a variety of potential targeted treatments, type 2 diabetes represents a promising focus for a precision health approach to reduce the impact of cognitive decline and dementia in older adults.

    View details for PubMedID 27899872

  • Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease JAMA NEUROLOGY Davis, M. Y., Johnson, C. O., Leverenz, J. B., Weintraub, D., Trojanowski, J. Q., Chen-Plotkin, A., Van Deerlin, V. M., Quinn, J. F., Chung, K. A., Peterson-Hiller, A. L., Rosenthal, L. S., Dawson, T., Albert, M. S., Goldman, J. G., Stebbins, G. T., Bernard, B., Wszolek, Z. K., Ross, O. A., Dickson, D. W., Eidelberg, D., Mattis, P. J., Niethammer, M., Yearout, D., Hu, S., Cholerton, B. A., Smith, M., Mata, I. F., Montine, T. J., Edwards, K. L., Zabetian, C. P. 2016; 73 (10): 1217–24

    Abstract

    Parkinson disease (PD) is heterogeneous in symptom manifestation and rate of progression. Identifying factors that influence disease progression could provide mechanistic insight, improve prognostic accuracy, and elucidate novel therapeutic targets.To determine whether GBA mutations and the E326K polymorphism modify PD symptom progression.The entire GBA coding region was screened for mutations and E326K in 740 patients with PD enrolled at 7 sites from the PD Cognitive Genetics Consortium. Detailed longitudinal motor and cognitive assessments were performed with patients in the on state.Linear regression was used to test for an association between GBA genotype and motor progression, with the Movement Disorder Society-sponsored version of the Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III) score at the last assessment as the outcome and GBA genotype as the independent variable, with adjustment for levodopa equivalent dose, sex, age, disease duration, MDS-UPDRS III score at the first assessment, duration of follow-up, and site. Similar methods were used to examine the association between genotype and tremor and postural instability and gait difficulty (PIGD) scores. To examine the effect of GBA genotype on cognitive progression, patients were classified into those with conversion to mild cognitive impairment or dementia during the study (progression) and those without progression. The association between GBA genotype and progression status was then tested using logistic regression, adjusting for sex, age, disease duration, duration of follow-up, years of education, and site.Of the total sample of 733 patients who underwent successful genotyping, 226 (30.8%) were women and 507 (69.2%) were men (mean [SD] age, 68.1 [8.8] years). The mean (SD) duration of follow-up was 3.0 (1.7) years. GBA mutations (β = 4.65; 95% CI, 1.72-7.58; P = .002), E326K (β = 3.42; 95% CI, 0.66-6.17; P = .02), and GBA variants combined as a single group (β = 4.01; 95% CI, 1.95-6.07; P = 1.5 × 10-4) were associated with a more rapid decline in MDS-UPDRS III score. Combined GBA variants (β = 0.38; 95% CI, 0.23-0.53; P = .01) and E326K (β = 0.64; 95% CI, 0.43-0.86; P = .002) were associated with faster progression in PIGD scores, but not in tremor scores. A significantly higher proportion of E326K carriers (10 of 21 [47.6%]; P = .01) and GBA variant carriers (15 of 39 [38.5%]; P = .04) progressed to mild cognitive impairment or dementia.GBA variants predict a more rapid progression of cognitive dysfunction and motor symptoms in patients with PD, with a greater effect on PIGD than tremor. Thus, GBA variants influence the heterogeneity in symptom progression observed in PD.

    View details for DOI 10.1001/jamaneurol.2016.2245

    View details for Web of Science ID 000386122100011

    View details for PubMedID 27571329

    View details for PubMedCentralID PMC5056861

  • The Discovery of LRRK2 p.R1441S, a Novel Mutation for Parkinson's Disease, Adds to the Complexity of a Mutational Hotspot AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS Mata, I. F., Davis, M. Y., Lopez, A. N., Dorschner, M. O., Martinez, E., Yearout, D., Cholerton, B. A., Hu, S., Edwards, K. L., Bird, T. D., Zabetian, C. P. 2016; 171 (7): 925–30

    Abstract

    Mutations in the LRRK2 gene result in autosomal dominant, late onset Parkinson's disease (PD). Three such mutations (p.R1441C, p.R1441G, and p.R1441H) are known to occur within codon 1441, and haplotype analyses indicate that each one has arisen independently on multiple occasions. We sequenced the entire coding region of 18 casual genes for PD or other parkinsonian neurodegenerative disorders in the proband of a family with autosomal dominant PD. We discovered a new missense mutation in the LRRK2 gene, c.4321C>A (p.R1441S). The mutation was predicted to be highly deleterious in silico (Combined Annotation Dependent Depletion score of 25.5) and segregated with disease in the pedigree. The clinical characteristics of affected family members were similar to those described in PD families with other mutations in LRRK2 codon 1441 and included resting tremor, rigidity, bradykinesia, unilateral onset, and a good response to levodopa. Age at onset ranged from 41 to 76. Two of the affected members of the pedigree underwent detailed, longitudinal neuropsychological testing, and both displayed evidence of mild cognitive deficits at or slightly preceding the onset of motor symptoms. LRRK2 p.R1441S represents the fourth pathogenic mutation observed within codon 1441 and its discovery adds to the remarkable complexity of a mutational hotspot within the ROC domain of the LRRK2 protein. © 2016 Wiley Periodicals, Inc.

    View details for DOI 10.1002/ajmg.b.32452

    View details for Web of Science ID 000390662200002

    View details for PubMedID 27111571

    View details for PubMedCentralID PMC5028305

  • Clinical-pathologic correlations in vascular cognitive impairment and dementia BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE Flanagan, M., Larson, E. B., Latimer, C. S., Cholerton, B., Crane, P. K., Montine, K. S., White, L. R., Keene, C., Montine, T. J. 2016; 1862 (5): 945–51

    Abstract

    The most common causes of cognitive impairment and dementia are Alzheimer's disease (AD) and vascular brain injury (VBI), either independently, in combination, or in conjunction with other neurodegenerative disorders. The contribution of VBI to cognitive impairment and dementia, particularly in the context of AD pathology, has been examined extensively yet remains difficult to characterize due to conflicting results. Describing the relative contribution and mechanisms of VBI in dementia is important because of the profound impact of dementia on individuals, caregivers, families, and society, particularly the stability of health care systems with the rapidly increasing age of our population. Here we discuss relationships between pathologic processes of VBI and clinical expression of dementia, specific subtypes of VBI including microvascular brain injury, and what is currently known regarding contributions of VBI to the development and pathogenesis of the dementia syndrome. This article is part of a Special Issue entitled: Vascular Contributions to Cognitive Impairment and Dementia edited by M. Paul Murphy, Roderick A. Corriveau and Donna M. Wilcock.

    View details for DOI 10.1016/j.bbadis.2015.08.019

    View details for Web of Science ID 000374609200011

    View details for PubMedID 26319420

    View details for PubMedCentralID PMC4769968

  • The Relationship between Nutrient Status and Cognitive Performance in Persons with Parkinson's Disease Hiller, A., Murchison, C., Cholerton, B., Hu, S., Zabetian, C., Leverenz, J., Chung, K., Montine, T., Carney, N., Quinn, J. LIPPINCOTT WILLIAMS & WILKINS. 2016
  • Precision Medicine Clarity for the Complexity of Dementia AMERICAN JOURNAL OF PATHOLOGY Cholerton, B., Larson, E. B., Quinn, J. F., Zabetian, C. P., Mata, I. F., Keene, C., Flanagan, M., Crane, P. K., Grabowski, T. J., Montine, K. S., Montine, T. J. 2016; 186 (3): 500–506

    Abstract

    Three key elements to precision medicine are stratification by risk, detection of pathophysiological processes as early as possible (even before clinical presentation), and alignment of mechanism of action of intervention(s) with an individual's molecular driver(s) of disease. Used for decades in the management of some rare diseases and now gaining broad currency in cancer care, a precision medicine approach is beginning to be adapted to cognitive impairment and dementia. This review focuses on the application of precision medicine to address the clinical and biological complexity of two common neurodegenerative causes of dementia: Alzheimer disease and Parkinson disease.

    View details for DOI 10.1016/j.ajpath.2015.12.001

    View details for Web of Science ID 000370991800005

    View details for PubMedID 26724389

    View details for PubMedCentralID PMC4816691

  • GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease MOVEMENT DISORDERS Mata, I. F., Leverenz, J. B., Weintraub, D., Trojanowski, J. Q., Chen-Plotkin, A., Van Deerlin, V. M., Ritz, B., Rausch, R., Factor, S. A., Wood-Siverio, C., Quinn, J. F., Chung, K. A., Peterson-Hiller, A. L., Goldman, J. G., Stebbins, G. T., Bernard, B., Espay, A. J., Revilla, F. J., Devoto, J., Rosenthal, L. S., Dawson, T. M., Albert, M. S., Tsuang, D., Huston, H., Yearout, D., Hu, S., Cholerton, B. A., Montine, T. J., Edwards, K. L., Zabetian, C. P. 2016; 31 (1): 95–102

    Abstract

    Loss-of-function mutations in the GBA gene are associated with more severe cognitive impairment in PD, but the nature of these deficits is not well understood and whether common GBA polymorphisms influence cognitive performance in PD is not yet known.We screened the GBA coding region for mutations and the E326K polymorphism in 1,369 PD patients enrolled at eight sites from the PD Cognitive Genetics Consortium. Participants underwent assessments of learning and memory (Hopkins Verbal Learning Test-Revised), working memory/executive function (Letter-Number Sequencing Test and Trail Making Test A and B), language processing (semantic and phonemic verbal fluency), visuospatial abilities (Benton Judgment of Line Orientation), and global cognitive function (MoCA). We used linear regression to test for association between genotype and cognitive performance with adjustment for important covariates and accounted for multiple testing using Bonferroni's corrections.Mutation carriers (n = 60; 4.4%) and E326K carriers (n = 65; 4.7%) had a higher prevalence of dementia (mutations, odds ratio = 5.1; P = 9.7 × 10(-6) ; E326K, odds ratio = 6.4; P = 5.7 × 10(-7) ) and lower performance on Letter-Number Sequencing (mutations, corrected P[Pc ] = 9.0 × 10(-4) ; E326K, Pc  = 0.036), Trail Making B-A (mutations, Pc  = 0.018; E326K, Pc  = 0.018), and Benton Judgment of Line Orientation (mutations, Pc  = 0.0045; E326K, Pc  = 0.0013).Both GBA mutations and E326K are associated with a distinct cognitive profile characterized by greater impairment in working memory/executive function and visuospatial abilities in PD patients. The discovery that E326K negatively impacts cognitive performance approximately doubles the proportion of PD patients we now recognize are at risk for more severe GBA-related cognitive deficits.

    View details for DOI 10.1002/mds.26359

    View details for Web of Science ID 000369431300018

    View details for PubMedID 26296077

    View details for PubMedCentralID PMC4724255

  • Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised ARQUIVOS DE NEURO-PSIQUIATRIA Sobreira, E., Pena-Pereira, M. A., Eckeli, A. L., Sobreira-Neto, M. A., Chagas, M. H. N., Foss, M. P., Cholerton, B., Zabetian, C. P., Mata, I. F., Tumas, V. 2015; 73 (11): 929–33

    Abstract

    The aim of the present study is to examine the accuracy of the Brazilian versions of the Montreal Cognitive Assessment (MoCA) and the Addenbrooke's Cognitive Examination-Revised (ACE-R) to screen for mild cognitive impairment (PDMCI) and dementia (PDD) in patients with Parkinson's disease (PD).Both scales were administered to a final convenience sample of 79 patients with PD. Patients were evaluated by a neurologist, a psychiatrist and a neuropsychologist using UPDRS, Hoehn and Yahr and Schwab and England scales, global deterioration scale, a psychiatric structured interview, Mattis Dementia Rating Scale and other cognitive tests.There were 32 patients with PDMCI and 17 patients with PDD. The MoCA and the ACE-R were able to discriminate patients with PDD from the others.Both scales showed to be useful to screen for dementia but not for mild cognitive impairment in patients with PD.

    View details for DOI 10.1590/0004-282X20150156

    View details for Web of Science ID 000364331900010

    View details for PubMedID 26517216

  • The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease MOLECULAR NEURODEGENERATION Mata, I. F., Jang, Y., Kim, C., Hanna, D. S., Dorschner, M. O., Samii, A., Agarwal, P., Roberts, J. W., Klepitskaya, O., Shprecher, D. R., Chung, K. A., Factor, S. A., Espay, A. J., Revilla, F. J., Higgins, D. S., Litvan, I., Leverenz, J. B., Yearout, D., Inca-Martinez, M., Martinez, E., Thompson, T. R., Cholerton, B. A., Hu, S., Edwards, K. L., Kim, K., Zabetian, C. P. 2015; 10: 50

    Abstract

    To identify the causal gene in a multi-incident U.S. kindred with Parkinson's disease (PD).We characterized a family with a classical PD phenotype in which 7 individuals (5 males and 2 females) were affected with a mean age at onset of 46.1 years (range, 29-57 years). We performed whole exome sequencing on 4 affected and 1 unaffected family members. Sanger-sequencing was then used to verify and genotype all candidate variants in the remainder of the pedigree. Cultured cells transfected with wild-type or mutant constructs were used to characterize proteins of interest.We identified a missense mutation (c.574G > A; p.G192R) in the RAB39B gene that closely segregated with disease and exhibited X-linked dominant inheritance with reduced penetrance in females. The mutation occurred in a highly conserved amino acid residue and was not observed among 87,725 X chromosomes in the Exome Aggregation Consortium dataset. Sequencing of the RAB39B coding region in 587 familial PD cases yielded two additional mutations (c.428C > G [p.A143G] and c.624_626delGAG [p.R209del]) that were predicted to be deleterious in silico but occurred in families that were not sufficiently informative to assess segregation with disease. Experiments in PC12 and SK-N-BE(2)C cells demonstrated that p.G192R resulted in mislocalization of the mutant protein, possibly by altering the structure of the hypervariable C-terminal domain which mediates intracellular targeting.Our findings implicate RAB39B, an essential regulator of vesicular-trafficking, in clinically typical PD. Further characterization of normal and aberrant RAB39B function might elucidate important mechanisms underlying neurodegeneration in PD and related disorders.

    View details for DOI 10.1186/s13024-015-0045-4

    View details for Web of Science ID 000361585700001

    View details for PubMedID 26399558

    View details for PubMedCentralID PMC4581468

  • Cognitive Profile of LRRK2-Related Parkinson's Disease MOVEMENT DISORDERS Srivatsal, S., Cholerton, B., Leverenz, J. B., Wszolek, Z. K., Uitti, R. J., Dickson, D. W., Weintraub, D., Trojanowski, J. Q., Van Deerlin, V. M., Quinn, J. F., Chung, K. A., Peterson, A. L., Factor, S. A., Wood-Siverio, C., Goldman, J. G., Stebbins, G. T., Bernard, B., Ritz, B., Rausch, R., Espay, A. J., Revilla, F. J., Devoto, J., Rosenthal, L. S., Dawson, T. M., Albert, M. S., Mata, I. F., Hu, S., Montine, K. S., Johnson, C., Montine, T. J., Edwards, K. L., Zhang, J., Zabetian, C. P. 2015; 30 (5): 728–33

    Abstract

    Increasing evidence suggests that genetic factors play a role in the variability associated with cognitive performance in Parkinson's disease (PD). Mutations in the LRRK2 gene are the most common cause of monogenic PD; however, the cognitive profile of LRRK2-related PD is not well-characterized.A cohort of 1,447 PD patients enrolled in the PD Cognitive Genetics Consortium was screened for LRRK2 mutations and completed detailed cognitive testing. Associations between mutation carrier status and cognitive test scores were assessed using linear regression models.LRRK2 mutation carriers (n = 29) demonstrated better performance on the Mini Mental State Examination (P = 0.03) and the Letter-Number Sequencing Test (P = 0.005). A smaller proportion of LRRK2 carriers were demented (P = 0.03).Our cross-sectional study demonstrates better performance on certain cognitive tests, as well as lower rates of dementia in LRRK2-related PD. Future longitudinal studies are needed to determine whether LRRK2 mutation carriers exhibit slower cognitive decline. © 2015 International Parkinson and Movement Disorder Society.

    View details for DOI 10.1002/mds.26161

    View details for Web of Science ID 000352790700019

    View details for PubMedID 25650144

    View details for PubMedCentralID PMC4397146

  • CSF tau and tau/A beta(42) predict cognitive decline in Parkinson's disease PARKINSONISM & RELATED DISORDERS Liu, C., Cholerton, B., Shi, M., Ginghina, C., Cain, K. C., Auinger, P., Zhang, J., Parkinson Study Grp DATATOP 2015; 21 (3): 271–76

    Abstract

    A substantial proportion of patients with Parkinson's disease (PD) have concomitant cognitive dysfunction. Identification of biomarker profiles that predict which PD patients have a greater likelihood for progression of cognitive symptoms is pressingly needed for future treatment and prevention approaches.Subjects were drawn from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study, a large clinical trial that enrolled initially untreated PD patients. For the current study, Phase One encompassed trial baseline until just prior to levodopa administration (n = 403), and Phase Two spanned the initiation of levodopa treatment until the end of cognitive follow-up (n = 305). Correlations and linear mixed models were performed to determine cross-sectional and longitudinal associations between baseline amyloid β1-42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) and measures of memory and executive function. Analyses also considered APOE genotype and tremor- vs. rigidity-dominant phenotype.No association was found between baseline CSF biomarkers and cognitive test performance during Phase One. However, once levodopa treatment was initiated, higher p-tau and p-tau/Aβ42 predicted subsequent decline on cognitive tasks involving both memory and executive functions. The interactions between biomarkers and cognition decline did not appear to be influenced by levodopa dosage, APOE genotype or motor phenotype.The current study has, for the first time, demonstrated the possible involvement of tau species, whose gene (MAPT) has been consistently linked to the risk of PD by genome-wide association studies, in the progression of cognitive symptoms in PD.

    View details for DOI 10.1016/j.parkreldis.2014.12.027

    View details for Web of Science ID 000350930100019

    View details for PubMedID 25596881

    View details for PubMedCentralID PMC4603566

  • Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study ALZHEIMERS & DEMENTIA Breitner, J., Baker, L., Drye, L., Evans, D., Lyketsos, C., Ryan, L., Zandi, P., Saucedo, H., Anau, J., Cholerton, B., Kramer, K., Casper, A., Meinert, C., Martin, B., Jenkins, G., McCaffrey, L., Meinert, J., Vaidya, V., Abuja, A., May, P., Ashe, K., Steinberg, M., Brandt, J., Pedroso, J. J., Bergey, A., Gogel, C., Smith, L., Kraus, J., Stern, R. A., Green, R. C., Gavett, B., Mwicigi, J., Baldwin, L., McGowan, T., Johnson, P., Qiu, W., Frederick, J., Raghavan, S., Rossi, C., Mandell, A., Dinizo, D., Roth, M., Porsteinsson, A., Ismail, M., Weber, M., Brand, C., Richard, J., Stear, K., Schepp, S., Cosman, K., Martin, K., Craft, S., Dahl, D., Garrett, G., Tidwell, J., Thielke, S., Smith, L., Arbuckle, M., Strong, W., Ladenberg, J., Callaghan, M., Watson, S., Skinner, J., Bowton, K., Sabbagh, M., Belden, C., Liebsack, C., Davis, K., Arnieri, L., Malek-Ahmadi, M., Nicholson, L., Jacobson, S., Schwartz, E., Mullan, M., Luis, C., Parrish, J., Faircloth, M., Ervin, T., Girard, J., Burke, D., Keegan, A., ADAPT-FS Res Grp 2015; 11 (2): 216–25

    Abstract

    The Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) and Follow-up Study (ADAPT-FS) examined effects of naproxen and celecoxib on cognition in the elderly. We report here results describing trajectories of cognitive evaluation test scores.A total of 2356 participants completed baseline and at least one follow-up cognitive evaluation between 2001 and 2004. Study treatments were discontinued in 2004, but participants were followed until 2007. A total of 1537 participants were reevaluated in 2010 to 2011. Outcomes include seven cognitive evaluations administered yearly in person in ADAPT and three of these evaluations that were administered by telephone near the end of ADAPT and again in ADAPT-FS.There were no important differences over time by treatment group on any ADAPT cognitive measure, a global composite, or the three cognitive measures reassessed in ADAPT-FS by telephone.Treatment for 1 to 3 years with naproxen or celecoxib did not protect against cognitive decline in older adults with a family history of AD.

    View details for DOI 10.1016/j.jalz.2014.03.009

    View details for Web of Science ID 000351255100011

    View details for PubMedID 25022541

    View details for PubMedCentralID PMC4287453

  • Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E epsilon 4 Carriers and Adults with Mild Cognitive Impairment JOURNAL OF ALZHEIMERS DISEASE Hanson, A. J., Bayer, J. L., Baker, L. D., Cholerton, B., VanFossen, B., Trittschuh, E., Rissman, R. A., Donohue, M. C., Moghadam, S. H., Plymat, S. R., Craft, S. 2015; 48 (1): 205–18

    Abstract

    High intake of saturated fat (SF) and glycemic index (GI) foods is a risk factor for sporadic Alzheimer's disease. Meal challenges may elucidate mechanisms that contribute to this risk, enabling development of targeted interventions.To assess cognitive and metabolic changes after a meal high in SF and GI calories (HIGH) versus a meal low in these macronutrients (LOW) in older adults with and without cognitive impairment, and with and without the apolipoprotein E4 risk factor.46 adults with either cognitive impairment (CI) or normal cognition (NC) ingested a LOW (25% total fat, 7% SF, GI <55) and a HIGH meal (50% total fat, 25% SF, GI >70) in a blinded random fashion. Participants then underwent cognitive testing and blood sampling for metabolic and Alzheimer's disease biomarkers. Data were analyzed using repeated measures ANOVA and Spearman correlations.E4-adults with NC demonstrated lower delayed memory scores after the HIGH compared to the LOW meal, whereas normal E4+ and CI E4- groups had higher scores after the HIGH meal (ANOVA p = 0.03). These findings were associated with meal-induced changes in glucose (p = 0.05), insulin (p = 0.004), triglycerides (p <  0.01), and plasma Aβ42 (p = 0.05).These preliminary data suggest that cognitive performance of adults without CI may worsen following high SF and sugar meals, whereas adults with CI or those at risk for CI due to E4 status may benefit acutely from such meals. Furthermore, plasma Aβ was affected by meal type, suggesting a relationship between metabolic response and amyloid regulation.

    View details for DOI 10.3233/JAD-150273

    View details for Web of Science ID 000360931700019

    View details for PubMedID 26401941

  • Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia JOURNAL OF ALZHEIMERS DISEASE Claxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan, A., Callaghan, M., Arbuckle, M., Behl, C., Craft, S. 2015; 44 (3): 897–906

    Abstract

    Previous trials have shown promising effects of intranasally administered insulin for adults with Alzheimer's disease dementia (AD) or amnestic mild cognitive impairment (MCI). These trials used regular insulin, which has a shorter half-life compared to long-lasting insulin analogues such as insulin detemir. The current trial examined whether intranasal insulin detemir improves cognition or daily functioning for adults with MCI or AD. Sixty adults diagnosed with MCI or mild to moderate AD received placebo (n = 20), 20 IU of insulin detemir (n = 21), or 40 IU of insulin detemir (n = 19) for 21 days, administered with a nasal drug delivery device. Results revealed a treatment effect for the memory composite for the 40 IU group compared with placebo (p < 0.05). This effect was moderated by APOE status (p < 0.05), reflecting improvement for APOE-ε4 carriers (p < 0.02), and worsening for non-carriers (p < 0.02). Higher insulin resistance at baseline predicted greater improvement with the 40 IU dose (r = 0.54, p < 0.02). Significant treatment effects were also apparent for verbal working memory (p < 0.03) and visuospatial working memory (p < 0.04), reflecting improvement for subjects who received the high dose of intranasal insulin detemir. No significant differences were found for daily functioning or executive functioning. In conclusion, daily treatment with 40 IU insulin detemir modulated cognition for adults with AD or MCI, with APOE-related differences in treatment response for the primary memory composite. Future research is needed to examine the mechanistic basis of APOE-related treatment differences, and to further assess the efficacy and safety of intranasal insulin detemir.

    View details for DOI 10.3233/JAD-141791

    View details for Web of Science ID 000349616000018

    View details for PubMedID 25374101

  • APOE, MAPT, and SNCA Genes and Cognitive Performance in Parkinson Disease JAMA NEUROLOGY Mata, I. F., Leverenz, J. B., Weintraub, D., Trojanowski, J. Q., Hurtig, H. I., Van Deerlin, V. M., Ritz, B., Rausch, R., Rhodes, S. L., Factor, S. A., Wood-Siverio, C., Quinn, J. F., Chung, K. A., Peterson, A. L., Espay, A. J., Revilla, F. J., Devoto, J., Hu, S., Cholerton, B. A., Wan, J. Y., Montine, T. J., Edwards, K. L., Zabetian, C. P. 2014; 71 (11): 1405–12

    Abstract

    Cognitive impairment is a common and disabling problem in Parkinson disease (PD) that is not well understood and is difficult to treat. Identification of genetic variants that influence the rate of cognitive decline or pattern of early cognitive deficits in PD might provide a clearer understanding of the etiopathogenesis of this important nonmotor feature.To determine whether common variation in the APOE, MAPT, and SNCA genes is associated with cognitive performance in patients with PD.We studied 1079 PD patients from 6 academic centers in the United States who underwent assessments of memory (Hopkins Verbal Learning Test-Revised [HVLT-R]), attention and executive function (Letter-Number Sequencing Test and Trail Making Test), language processing (semantic and phonemic verbal fluency tests), visuospatial skills (Benton Judgment of Line Orientation test), and global cognitive function (Montreal Cognitive Assessment). Participants underwent genotyping for the APOE ε2/ε3/ε4 alleles, MAPT H1/H2 haplotypes, and SNCA rs356219. We used linear regression to test for association between genotype and baseline cognitive performance with adjustment for age, sex, years of education, disease duration, and site. We used a Bonferroni correction to adjust for the 9 comparisons that were performed for each gene.Nine variables derived from 7 psychometric tests.The APOE ε4 allele was associated with lower performance on the HVLT-R Total Recall (P = 6.7 × 10(-6); corrected P [Pc] = 6.0 × 10(-5)), Delayed Recall (P = .001; Pc = .009), and Recognition Discrimination Index (P = .004; Pc = .04); a semantic verbal fluency test (P = .002; Pc = .02); the Letter-Number Sequencing Test (P = 1 × 10(-5); Pc = 9 × 10(-5)); and Trail Making Test B minus Trail Making Test A (P = .002; Pc = .02). In a subset of 645 patients without dementia, the APOE ε4 allele was associated with lower scores on the HVLT-R Total Recall (P = .005; Pc = .045) and the semantic verbal fluency (P = .005; Pc = .045) measures. Variants of MAPT and SNCA were not associated with scores on any tests.Our data indicate that the APOE ε4 allele is an important predictor of cognitive function in PD across multiple domains. Among PD patients without dementia, the APOE ε4 allele was only associated with lower performance on word list learning and semantic verbal fluency, a pattern more typical of the cognitive deficits seen in early Alzheimer disease than PD.

    View details for DOI 10.1001/jamaneurol.2014.1455

    View details for Web of Science ID 000345145300010

    View details for PubMedID 25178429

    View details for PubMedCentralID PMC4227942

  • People with Parkinson's Disease and Normal MMSE Score Have a Broad Range of Cognitive Performance MOVEMENT DISORDERS Burdick, D. J., Cholerton, B., Watson, G. S., Siderowf, A., Trojanowski, J. Q., Weintraub, D., Ritz, B., Rhodes, S. L., Rausch, R., Factor, S. A., Wood-Siverio, C., Quinn, J. F., Chung, K. A., Srivatsal, S., Edwards, K. L., Montine, T. J., Zabetian, C. P., Leverenz, J. B. 2014; 29 (10): 1258–64

    Abstract

    Cognitive impairment, including dementia, is common in Parkinson's disease (PD). The Mini-Mental State Examination (MMSE) has been recommended as a screening tool for Parkinson's disease dementia (PDD), with values below 26 indicative of possible dementia. Using a detailed neuropsychological battery, we examined the range of cognitive impairment in PD patients with an MMSE score of 26 or higher. In this multicenter, cross-sectional, observational study, we performed neuropsychological testing in a sample of 788 PD patients with MMSE scores of 26 or higher. Evaluation included tests of global cognition, executive function, language, memory, and visuospatial skills. A consensus panel reviewed results for 342 subjects and assigned a diagnosis of no cognitive impairment, mild cognitive impairment, or dementia. Sixty-seven percent of the 788 subjects performed 1.5 standard deviations below the normative mean on at least one test. On eight of the 15 tests, more than 20% of subjects scored 1.5 standard deviations or more below the normative mean. Greatest impairments were found on Hopkins Verbal Learning and Digit Symbol Coding tests. The sensitivity of the MMSE to detect dementia was 45% in a subset of participants who underwent clinical diagnostic procedures. A remarkably wide range of cognitive impairment can be found in PD patients with a relatively high score on the MMSE, including a level of cognitive impairment consistent with dementia. Given these findings, clinicians must be aware of the limitations of the MMSE in detecting cognitive impairment, including dementia, in PD.

    View details for DOI 10.1002/mds.25924

    View details for Web of Science ID 000342164600036

    View details for PubMedID 25073717

    View details for PubMedCentralID PMC4162839

  • Evaluation of Mild Cognitive Impairment Subtypes in Parkinson's Disease MOVEMENT DISORDERS Cholerton, B. A., Zabetian, C. P., Wan, J. Y., Montine, T. J., Quinn, J. F., Mata, I. F., Chung, K. A., Peterson, A., Espay, A. J., Revilla, F. J., Devoto, J., Watson, G., Hu, S., Leverenz, J. B., Edwards, K. L. 2014; 29 (6): 756–64

    Abstract

    Mild cognitive impairment in Parkinson's disease (PD-MCI) is common and increases the risk for dementia. Establishing distinct PD-MCI cognitive subtypes could be valuable for eventually predicting those most likely to convert to dementia. However, the study of PD-MCI subtypes has not yielded consistent results among cohorts. To determine whether there are distinct cognitive subtypes among participants diagnosed with PD-MCI in the Pacific Northwest Udall Center Clinical Consortium, we cognitively subtyped 95 patients with PD-MCI, using the Movement Disorders Society Task Force diagnostic guidelines. Psychometric test scores were then subjected to principle components factor analysis to determine whether similar cognitive subgroups could be identified using statistical methodology. Multiple-domain PD-MCI was diagnosed in 95% of the sample, and a range of cognitive impairments were noted. Factor analysis yielded seven factors and demonstrated overlap of phonemic verbal fluency on two factors, as well as the loading of verbal fluency on the same factor as a visuospatial measure; however, these factors did not partition the sample into distinct cognitive subtypes. Separation of cognitive subtypes based on the current PD-MCI criteria, or via statistical methods, may not provide sufficient information to describe distinct PD groups. Future efforts to validate the PD-MCI criteria and identify combinations of genetic or other risk factors for cognitive impairment are warranted.

    View details for DOI 10.1002/mds.25875

    View details for Web of Science ID 000335363300010

    View details for PubMedID 24710804

    View details for PubMedCentralID PMC4013249

  • Cerebrospinal Fluid alpha-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort AMERICAN JOURNAL OF PATHOLOGY Stewart, T., Liu, C., Ginghina, C., Cain, K. C., Auinger, P., Cholerton, B., Shi, M., Zhang, J., Parkinson Study Grp DATATOP Invest 2014; 184 (4): 966–75

    Abstract

    Most patients with Parkinson disease (PD) develop both cognitive and motor impairment, and biomarkers for progression are urgently needed. Although α-synuclein is altered in cerebrospinal fluid of patients with PD, it is not known whether it predicts motor or cognitive deterioration. We examined clinical data and α-synuclein in >300 unmedicated patients with PD who participated in the deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP) study, with up to 8 years of follow-up. Longitudinal measures of motor and cognitive function were studied before (phase 1) and during (phase 2) levodopa therapy; cerebrospinal fluid was collected at the beginning of each phase. Correlations and linear mixed models were used to assess α-synuclein association with disease severity and prediction of progression in the subsequent follow-up period. Despite decreasing α-synuclein (phase 1 to phase 2 change of -0.05 ± 0.21 log-transformed values, P < 0.001), no correlations were observed between α-synuclein and motor symptoms. Longitudinally, lower α-synuclein predicted better preservation of cognitive function by several measures [Selective Reminding Test total recall α-synuclein × time interaction effect coefficient, -0.12 (P = 0.037); delayed recall, -0.05 (P = 0.002); New Dot Test, -0.03 (P = 0.002)]. Thus, α-synuclein, although not clinically useful for motor progression, might predict cognitive decline, and future longitudinal studies should include this outcome for further validation.

    View details for DOI 10.1016/j.ajpath.2013.12.007

    View details for Web of Science ID 000333548600009

    View details for PubMedID 24625392

    View details for PubMedCentralID PMC3969999

  • Insulin, cognition, and dementia EUROPEAN JOURNAL OF PHARMACOLOGY Cholerton, B., Baker, L. D., Craft, S. 2013; 719 (1-3): 170–79

    Abstract

    Cognitive disorders of aging represent a serious threat to the social and economic welfare of current society. It is now widely recognized that pathology related to such conditions, particularly Alzheimer's disease, likely begins years or decades prior to the onset of clinical dementia symptoms. This revelation has led researchers to consider candidate mechanisms precipitating the cascade of neuropathological events that eventually lead to clinical Alzheimer's disease. Insulin, a hormone with potent effects in the brain, has recently received a great deal of attention for its potential beneficial and protective role in cognitive function. Insulin resistance, which refers to the reduced sensitivity of target tissues to the favorable effects of insulin, is related to multiple chronic conditions known to impact cognition and increase dementia risk. With insulin resistance-associated conditions reaching epidemic proportions, the prevalence of Alzheimer's disease and other cognitive disorders will continue to rise exponentially. Fortunately, these chronic insulin-related conditions are amenable to pharmacological intervention. As a result, novel therapeutic strategies that focus on increasing insulin sensitivity in the brain may be an important target for protecting or treating cognitive decline. The following review will highlight our current understanding of the role of insulin in brain, potential mechanisms underlying the link between insulin resistance and dementia, and current experimental therapeutic strategies aimed at improving cognitive function via modifying the brain's insulin sensitivity.

    View details for DOI 10.1016/j.ejphar.2013.08.008

    View details for Web of Science ID 000327487200020

    View details for PubMedID 24070815

    View details for PubMedCentralID PMC5405627

  • Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) The Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group ALZHEIMERS & DEMENTIA Breitner, J., Baker, L., Drye, L., Evans, D., Lyketsos, C., Ryan, L., Zandi, P., Baker, L., Breitner, J., Saucedo, H., Anau, J., Cholerton, B., Kramer, K., Zandi, P., Drye, L., Casper, A., Meinert, C., Martin, B., Jenkins, G., McCaffrey, L., Meinert, J., Vaidya, V., Ahuja, A., May, P., Ryan, L., Lyketsos, C. G., Steinberg, M., Brandt, J., Pedroso, J. J., Bergey, A., Gogel, C., Smith, L., Kraus, J., Stern, R. A., Green, R. C., Gavett, B., Mwicigi, J., Baldwin, L., McGowan, T., Johnson, P., Qiu, W., Frederick, J., Raghavan, S., Rossi, C., Mandell, A., Dinizo, D., Roth, M., Porsteinsson, A., Ismail, M., Weber, M., Brand, C., Richard, J., Stear, K., Schepp, S., Cosman, K., Martin, K., Craft, S., Baker, L., Dahl, D., Garrett, G., Tidwell, J., Thielke, S., Smith, L., Arbuckle, M., Strong, W., Ladenberg, J., Callaghan, M., Watson, S., Skinner, J., Bowton, K., Sabbagh, M., Belden, C., Liebsack, C., Davis, K., Arnieri, L., Malek-Ahmadi, M., Nicholson, L., Jacobson, S., Schwartz, E., Mullan, M., Luis, C., Parrish, J., Faircloth, M., Ervin, T., Girard, J., Burke, D., Keegan, A., Evans, D., Alzheimer's Dis Antiinflammatory 2013; 9 (6): 714–23

    Abstract

    The Alzheimer's Disease Anti-inflammatory Prevention Trial Follow-up Study (ADAPT-FS) was designed to evaluate the efficacy of naproxen and celecoxib for the primary prevention of Alzheimer's disease (AD) several years after cessation of treatment in ADAPT.ADAPT was a randomized, double-masked, multicenter clinical trial of naproxen or celecoxib vs placebo (1:1:1.5 assignment ratio) at six U.S.-based clinics. The trial enrolled 2528 people between 2001 and 2004. Treatments were discontinued in December 2004 and participants were monitored regularly until 2007. In 2010 and 2011, ADAPT-FS screened 1537 participants by telephone and, if indicated, examined them in person using standardized clinical assessments. The primary outcome was time to diagnosis of AD. Death index searches were performed for participants not located.Eighty-nine additional AD events were identified (24 celecoxib, 25 naproxen, and 40 placebo) yielding a total of 161 events (48 [6.6% of randomized participants] celecoxib, 43 [6.0%] naproxen, and 70 [6.5%] placebo) across ADAPT and ADAPT-FS. Adjusted hazard ratios (HRs) comparing each treatment with placebo showed no overall reduction in risk of AD: HR celecoxib vs placebo, 1.03 (95% confidence interval [CI], 0.72-1.50; P = .86); HR naproxen vs placebo, 0.92 (95% CI, 0.62-1.35; P = .66). There were 349 deaths (110 [15.2%] celecoxib, 96 [13.4%] naproxen, and 143 [13.2%] placebo). Risk of death was similar for the naproxen- and placebo-assigned groups (HR, 0.99; 95% CI, 0.76-1.28; P = .93) and slightly higher for celecoxib compared with the placebo-assigned group (HR, 1.15; 95% CI, 0.90-1.48; P = .27).These results acquired during a follow-up of approximately 7 years (which included a median of less than 1.5 years of treatment) do not support the hypothesis that celecoxib or naproxen prevent AD in adults with a family history of dementia.

    View details for DOI 10.1016/j.jalz.2012.11.012

    View details for Web of Science ID 000327172700012

    View details for PubMedID 23562431

    View details for PubMedCentralID PMC3823756

  • Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington ALZHEIMERS & DEMENTIA Watson, G., Cholerton, B. A., Gross, R. G., Weintraub, D., Zabetian, C. P., Trojanowski, J. Q., Montine, T. J., Siderowf, A., Leverenz, J. B. 2013; 9 (5): 609–14

    Abstract

    Cognitive impairment (CI) and behavioral disturbances can be the earliest symptoms of Parkinson's disease (PD), ultimately afflict the vast majority of PD patients, and increase caregiver burden. Our two Morris K. Udall Centers of Excellence for Parkinson's Disease Research were supported by the National Institute of Neurological Disorders and Stroke (NINDS) in an effort to recommend a comprehensive yet practical approach to cognitive and behavioral assessment to further collaborative research. We recommend a stepwise approach with two levels of standardized evaluation to establish a common battery, as well as an alternative testing recommendation for severely impaired subjects, and review supplemental tests that may be useful in specific research settings. Our flexible approach may be applied to studies with varying emphasis on cognition and behavior, does not place undue burden on participants or resources, and has a high degree of compatibility with existing test batteries to promote collaboration.

    View details for DOI 10.1016/j.jalz.2012.07.006

    View details for Web of Science ID 000324724500016

    View details for PubMedID 23164549

    View details for PubMedCentralID PMC3612566

  • Insulin and Alzheimer's Disease: Untangling the Web ALZHEIMER'S DISEASE: ADVANCES FOR A NEW CENTURY Craft, S., Cholerton, B., Baker, L. D. edited by Perry, G., Zhu, Smith, M. A., Sorensen, A., Avila, J. 2013; 3: 263–75
  • Insulin and Alzheimer's Disease: Untangling the Web JOURNAL OF ALZHEIMERS DISEASE Craft, S., Cholerton, B., Baker, L. D. 2013; 33: S263–S275

    Abstract

    The recognition of Alzheimer's disease (AD) as a heterogeneous disorder that results from incremental pathological changes in dynamic organismic systems is essential to move beyond the unidimensional approaches to prevention and therapy that have proven largely ineffective to date. Biological systems related to insulin metabolism are arguably the most critical regulators of longevity and corporeal aging. Our work has focused on identifying the relationship of the insulin network to brain aging, and determining the mechanisms through which insulin dysregulation promotes AD pathological processes. Candidate mechanisms include the effects of insulin on amyloid-β, cerebral glucose metabolism, vascular function, lipid metabolism, and inflammation/oxidative stress. It is likely that different nodes of the insulin network are perturbed for subgroups of AD patients, or that for some subgroups, pathways independent of insulin are critical pathogenetic factors. New methods from systems network analyses may help to identify these subgroups, which will be critical for devising tailored prevention and treatment strategies. In the following review, we will provide a brief description of the role of insulin in normal brain function, and then focus more closely on recent evidence regarding the mechanisms through which disruption of that role may promote AD pathological processes. Finally, we will discuss the implications of this area for AD therapeutics and prevention.

    View details for DOI 10.3233/JAD-2012-129042

    View details for Web of Science ID 000314447600026

    View details for PubMedID 22936011

  • Sex and ApoE Genotype Differences in Treatment Response to Two Doses of Intranasal Insulin in Adults with Mild Cognitive Impairment or Alzheimer's Disease JOURNAL OF ALZHEIMERS DISEASE Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G., Cholerton, B., Plymate, S. R., Arbuckle, M., Craft, S. 2013; 35 (4): 789–97

    Abstract

    A previous clinical trial demonstrated that four months of treatment with intranasal insulin improves cognition and function for patients with Alzheimer's disease (AD) or mild cognitive impairment (MCI), but prior studies suggest that response to insulin treatment may differ by sex and ApoE ε4 carriage. Thus, responder analyses using repeated measures analysis of covariance were completed on the trial's 104 participants with MCI or AD who received either placebo or 20 or 40 IU of insulin for 4 months, administered by a nasal delivery device. Results indicate that men and women with memory impairment responded differently to intranasal insulin treatment. On delayed story memory, men and women showed cognitive improvement when taking 20 IU of intranasal insulin, but only men showed cognitive improvement for the 40 IU dose. The sex difference was most apparent for ApoE ε4 negative individuals. For the 40 IU dose, ApoE ε4 negative men improved while ApoE ε4 negative women worsened. Their ApoE ε4 positive counterparts remained cognitively stable. This sex effect was not detected in functional measures. However, functional abilities were relatively preserved for women on either dose of intranasal insulin compared with men. Unlike previous studies with young adults, neither men nor women taking intranasal insulin exhibited a significant change in weight over 4 months of treatment.

    View details for DOI 10.3233/JAD-122308

    View details for Web of Science ID 000319345300012

    View details for PubMedID 23507773

    View details for PubMedCentralID PMC4144993

  • Pacific Northwest Udall Center of Excellence Clinical Consortium: Study Design and Baseline Cohort Characteristics JOURNAL OF PARKINSONS DISEASE Cholerton, B. A., Zabetian, C. P., Quinn, J. F., Chung, K. A., Peterson, A., Espay, A. J., Revilla, F. J., Devoto, J., Watson, G., Hu, S., Edwards, K. L., Montine, T. J., Leverenz, J. B. 2013; 3 (2): 205–14

    Abstract

    The substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD.To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data.Six hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference.A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p < 0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented.The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.

    View details for DOI 10.3233/JPD-130189

    View details for Web of Science ID 000319340700011

    View details for PubMedID 23938350

    View details for PubMedCentralID PMC3779428

  • Neuropathologic Correlates of Cognition in a Population-Based Sample JOURNAL OF ALZHEIMERS DISEASE Cholerton, B., Larson, E. B., Baker, L. D., Craft, S., Crane, P. K., Millard, S. P., Sonnen, J. A., Montine, T. J. 2013; 36 (4): 699–709

    Abstract

    Many cognitively normal older adults have underlying neuropathologic changes of Alzheimer's disease (AD), vascular brain injury (VBI), or Lewy body disease (LBD), which confer an increased risk of dementia. The current study focused on the association between multiple neuropathologic indices and performance on specific cognitive domains in a community sample of older adults. Of 438 participants in the Adult Changes in Thought population-based study of brain aging who were autopsied, 363 subjects had cognitive testing at their final study visit and were included. Associations were measured between performance on the Cognitive Abilities Screening Instrument prior to death and neuropathologic endpoints, including AD neuropathologic changes, LBD, cerebral amyloid angiopathy, and measures of VBI. Braak stage for neurofibrillary tangles, lower brain weight, and VBI as measured by cerebral cortical microvascular lesions (μVBI) explained a significant proportion of the variance associated with global cognitive test performance (R2 = 0.31, p < 0.0001) both in the entire sample and when analysis was restricted to non-demented subjects (R2 = 0.23, p < 0.0001). Specific cognitive domains were differentially related to neuropathologic lesion type: memory and executive function with AD pathologic changes and cortical μVBI, executive function with subcortical μVBI, and visuospatial construction with LBD. Thus, neuropathologic lesions of LBD and μVBI are associated with poorer cognitive performance over and above AD neuropathologic changes in subjects without dementia in this cohort. These findings underscore that cognitive impairment is a complex convergent trait that has important implications for clinical investigation and medical management of older adults.

    View details for DOI 10.3233/JAD-130281

    View details for Web of Science ID 000322738000008

    View details for PubMedID 23666176

    View details for PubMedCentralID PMC3737376

  • Cognitive response to estradiol in postmenopausal women is modified by high cortisol NEUROBIOLOGY OF AGING Baker, L. D., Asthana, S., Cholerton, B. A., Wilkinson, C. W., Plymate, S. R., Green, P. S., Merriam, G. R., Fishel, M. A., Watson, G., Cherrier, M. M., Kletke, M. L., Mehta, P. D., Craft, S. 2012; 33 (4): 829.e9–20

    Abstract

    Estradiol has potent favorable effects on brain function and behavior in animals while in human trials, the results are inconsistent. A number of potential mediating variables influencing response to estradiol have been proposed to account for this variability, 1 of which includes stress. We conducted a placebo-controlled study to examine joint and independent effects of estradiol and elevated levels of the stress hormone cortisol on cognition and biomarkers of aging and neurodegenerative disease. Thirty-nine healthy postmenopausal women (56-84 years) received 0.10 mg/dL of transdermal 17β-estradiol (E2) or placebo for 8 weeks. During the last 4 days of the trial, subjects also received 90 mg/day (30 mg 3×/day) of oral hydrocortisone (CORT) to induce stress-level elevations in cortisol, or a matched placebo. The 4 groups thus included placebo (placebo patch/placebo pill), CORT-alone (placebo patch/hydrocortisone), E2-alone (estradiol patch/placebo pill), and E2+CORT (estradiol patch/hydrocortisone). Eight weeks of E2 increased plasma estradiol by 167%, and 4 days of CORT increased plasma cortisol by 119%. Overall, E2 had favorable effects on verbal memory (p = 0.03), working memory (p = 0.02), and selective attention (p = 0.04), and the magnitude of these effects was attenuated for E2+CORT. E2-alone and E2+CORT had opposing effects on plasma levels of the amyloid-β (Aβ) biomarker (Aβ40/42 ratio, p < 0.05), with the more favorable response observed for E2-alone. CORT-induced increases in insulin-like growth factor-1 were blunted by E2 coadministration. Our findings indicate that cognitive and physiological responses to estradiol are adversely affected by elevated stress hormone levels of cortisol in healthy postmenopausal women.

    View details for DOI 10.1016/j.neurobiolaging.2011.07.002

    View details for Web of Science ID 000301506800032

    View details for PubMedID 21855173

    View details for PubMedCentralID PMC3725779

  • Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Leoutsakos, J. S., Muthen, B. O., Breitner, J. C. S., Lyketsos, C. G., ADAPT Res Team 2012; 27 (4): 364–74

    Abstract

    We examined the effects of non-steroidal anti-inflammatory drugs on cognitive decline as a function of phase of pre-clinical Alzheimer disease.Given recent findings that cognitive decline accelerates as clinical diagnosis is approached, we used rate of decline as a proxy for phase of pre-clinical Alzheimer disease. We fit growth mixture models of Modified Mini-Mental State (3MS) Examination trajectories with data from 2388 participants in the Alzheimer's Disease Anti-inflammatory Prevention Trial and included class-specific effects of naproxen and celecoxib.We identified three classes: "no decline", "slow decline", and "fast decline", and examined the effects of celecoxib and naproxen on linear slope and rate of change by class. Inclusion of quadratic terms improved fit of the model (-2 log likelihood difference: 369.23; p < 0.001) but resulted in reversal of effects over time. Over 4 years, participants in the slow-decline class on placebo typically lost 6.6 3MS points, whereas those on naproxen lost 3.1 points (p-value for difference: 0.19). Participants in the fast-decline class on placebo typically lost 11.2 points, but those on celecoxib first declined and then gained points (p-value for difference from placebo: 0.04), whereas those on naproxen showed a typical decline of 24.9 points (p-value for difference from placebo: <0.0001).Our results appeared statistically robust but provided some unexpected contrasts in effects of different treatments at different times. Naproxen may attenuate cognitive decline in slow decliners while accelerating decline in fast decliners. Celecoxib appeared to have similar effects at first but then attenuated change in fast decliners.

    View details for DOI 10.1002/gps.2723

    View details for Web of Science ID 000301228600004

    View details for PubMedID 21560159

    View details for PubMedCentralID PMC3208130

  • Insulin and Sex Interactions in Older Adults with Mild Cognitive Impairment JOURNAL OF ALZHEIMERS DISEASE Cholerton, B., Baker, L. D., Trittschuh, E. H., Crane, P. K., Larson, E. B., Arbuckle, M., Saucedo, H., McCurry, S. M., Bowen, J. D., McCormick, W. C., Craft, S. 2012; 31 (2): 401–10

    Abstract

    Alzheimer's disease (AD) and other dementias are likely preceded by a protracted preclinical state. Thus, identification of biomarkers that signal potential points of intervention during this prodromal phase (during which patients are largely able to compensate for their cognitive deficits) is of paramount importance. Insulin is a pancreatic hormone with potent central nervous system effects, and insulin dysregulation has been implicated in the pathogenesis of both AD and vascular dementia. The aim of the current study was to determine whether circulating insulin differs as a function of mild cognitive impairment (MCI) diagnosis, and whether this relationship is mediated by sex and apolipoprotein E (APOE) genotype. A sample of 549 nondemented participants aged 65 and over from the Adult Changes in Thought community-based cohort underwent cognitive testing and blood draw to determine fasting levels of plasma insulin. Subjects were categorized as having normal cognitive functioning, amnestic MCI, or nonamnestic MCI. Results showed that the relationship between insulin and diagnostic category is moderated by sex, such that men with nonamnestic or amnestic MCI have higher fasting plasma insulin than cognitively normal men, while women with amnestic MCI have lower fasting plasma insulin than cognitively normal women. Exploratory analyses suggest that APOE ε4 genotype may further influence the relationship between sex and insulin. Future research will help determine whether insulin dysregulation results in differential effects on vascular function and AD pathology as a function of sex and/or APOE genotype.

    View details for DOI 10.3233/JAD-2012-120202

    View details for Web of Science ID 000307377300015

    View details for PubMedID 22571978

    View details for PubMedCentralID PMC3798013

  • High-Intensity Physical Activity Modulates Diet Effects on Cerebrospinal Amyloid-beta Levels in Normal Aging and Mild Cognitive Impairment JOURNAL OF ALZHEIMERS DISEASE Baker, L. D., Bayer-Carter, J. L., Skinner, J., Montine, T. J., Cholerton, B. A., Callaghan, M., Leverenz, J. B., Walter, B. K., Tsai, E., Postupna, N., Lampe, J., Craft, S. 2012; 28 (1): 137–46

    Abstract

    We previously showed that amyloid-β 1-42 (Aβ(42)) levels in cerebrospinal fluid (CSF) were markedly altered in response to a 4-week dietary intervention in normal aging and mild cognitive impairment (MCI). Here, we re-examined the data to assess whether diet-induced effects on CSF Aβ(42) were modulated by high intensity physical activity (hi-PA). Normal older adults (n = 18, mean age = 68.6 ± 7.4 y) and adults with amnestic MCI (n = 23, mean age = 68.0 ± 6.5 y) received a low saturated fat/low glycemic index (LOW) diet or a high saturated fat/high glycemic index (HIGH) diet, and CSF levels of Aβ(42), tau, and IL-8 were measured at baseline and week 4. Pre-study activity levels were assessed using a 7-d questionnaire, and weekly duration of hi-PA was quantified. At baseline, increased hi-PA in normals predicted lower CSF levels of tau (r = -0.54, p = 0.020) and IL-8 (r = -0.70, p = 0.025). Diet-induced effects on CSF Aβ(42) during the intervention study were modulated by hi-PA, and the nature of this effect differed for normals and MCI (ANOVA, p = 0.039). That is, for normal adults, increased hi-PA attenuated the effects of the HIGH diet on CSF Aβ(42) whereas in MCI, increased hi-PA potentiated the effects of the LOW diet. Our results suggest that normal adults who engage in hi-PA are less vulnerable to the pathological effects of an unhealthy diet, while in MCI, the benefit of a healthy diet on Aβ modulation is greatest when paired with hi-PA. Exercise may thus interact with diet to alter pathological processes that ultimately modify risk of Alzheimer's disease.

    View details for DOI 10.3233/JAD-2011-111076

    View details for Web of Science ID 000299311900012

    View details for PubMedID 21971406

    View details for PubMedCentralID PMC3280092

  • Effects of Varying Diagnostic Criteria on Prevalence of Mild Cognitive Impairment in a Community Based Sample JOURNAL OF ALZHEIMERS DISEASE Trittschuh, E. H., Crane, P. K., Larson, E. B., Cholerton, B., McCormick, W. C., McCurry, S. M., Bowen, J. D., Baker, L. D., Craft, S. 2011; 25 (1): 163–73

    Abstract

    Mild cognitive impairment (MCI) is proposed to be a prodrome to dementia in some older adults. However, the presentation of MCI in the community can differ substantially from clinic-based samples. The aim of the current study is to demonstrate the effects of different operational definitions of MCI on prevalence estimates in community-dwelling older adults. A consecutive series of 200 participants aged 65 and over from the Adult Changes in Thought (ACT) community-based cohort were approached to undergo comprehensive neuropsychological and medical evaluation; 159 were included in the final analyses. Nondemented subjects were categorized using various diagnostic criteria for MCI. In a novel approach, neuropsychological test scores were evaluated using an individualized benchmark as a point of test comparison, as well as traditional methods that entail comparison to age-based normative data. Diagnostic criteria were further subdivided by severity of impairment (1.0 vs. 1.5 standard deviations [sd] below the benchmark) and extent of impairment (based on a single test or an average of tests within a cognitive domain). MCI prevalence rates in the sample were highly dependent on these diagnostic factors, and varied from 11% to 92% of the sample. Older groups tended to show higher prevalence rates, although this was not the case across all diagnostic schemes. The use of an individualized benchmark, less severe impairment cutoff, and impairment on only a single test all produced higher rates of MCI. Longitudinal follow-up will determine whether varying diagnostic criteria improves sensitivity and specificity of the MCI diagnosis as a predictor for dementia.

    View details for DOI 10.3233/JAD-2011-101821

    View details for Web of Science ID 000293377700017

    View details for PubMedID 21368379

    View details for PubMedCentralID PMC3146555

  • Aerobic Exercise Improves Cognition for Older Adults with Glucose Intolerance, A Risk Factor for Alzheimer's Disease JOURNAL OF ALZHEIMERS DISEASE Baker, L. D., Frank, L. L., Foster-Schubert, K., Green, P. S., Wilkinson, C. W., McTiernan, A., Cholerton, B. A., Plymate, S. R., Fishel, M. A., Watson, G., Duncan, G. E., Mehta, P. D., Craft, S. 2010; 22 (2): 569–79

    Abstract

    Impaired glucose regulation is a defining characteristic of type 2 diabetes mellitus (T2DM) pathology and has been linked to increased risk of cognitive impairment and dementia. Although the benefits of aerobic exercise for physical health are well-documented, exercise effects on cognition have not been examined for older adults with poor glucose regulation associated with prediabetes and early T2DM. Using a randomized controlled design, twenty-eight adults (57-83 y old) meeting 2-h tolerance test criteria for glucose intolerance completed 6 months of aerobic exercise or stretching, which served as the control. The primary cognitive outcomes included measures of executive function (Trails B, Task Switching, Stroop, Self-ordered Pointing Test, and Verbal Fluency). Other outcomes included memory performance (Story Recall, List Learning), measures of cardiorespiratory fitness obtained via maximal-graded exercise treadmill test, glucose disposal during hyperinsulinemic-euglycemic clamp, body fat, and fasting plasma levels of insulin, cortisol, brain-derived neurotrophic factor, insulin-like growth factor-1, amyloid-β (Aβ40 and Aβ42). Six months of aerobic exercise improved executive function (MANCOVA, p=0.04), cardiorespiratory fitness (MANOVA, p=0.03), and insulin sensitivity (p=0.05). Across all subjects, 6-month changes in cardiorespiratory fitness and insulin sensitivity were positively correlated (p=0.01). For Aβ42, plasma levels tended to decrease for the aerobic group relative to controls (p=0.07). The results of our study using rigorous controlled methodology suggest a cognition-enhancing effect of aerobic exercise for older glucose intolerant adults. Although replication in a larger sample is needed, our findings potentially have important therapeutic implications for a growing number of adults at increased risk of cognitive decline.

    View details for DOI 10.3233/JAD-2010-100768

    View details for Web of Science ID 000284309200017

    View details for PubMedID 20847403

    View details for PubMedCentralID PMC3049111

  • Effects of Aerobic Exercise on Mild Cognitive Impairment A Controlled Trial ARCHIVES OF NEUROLOGY Baker, L. D., Frank, L. L., Foster-Schubert, K., Green, P. S., Wilkinson, C. W., McTiernan, A., Plymate, S. R., Fishel, M. A., Watson, G., Cholerton, B. A., Duncan, G. E., Mehta, P. D., Craft, S. 2010; 67 (1): 71–79

    Abstract

    To examine the effects of aerobic exercise on cognition and other biomarkers associated with Alzheimer disease pathology for older adults with mild cognitive impairment, and assess the role of sex as a predictor of response.Six-month, randomized, controlled, clinical trial.Veterans Affairs Puget Sound Health Care System clinical research unit.Thirty-three adults (17 women) with amnestic mild cognitive impairment ranging in age from 55 to 85 years (mean age, 70 years). Intervention Participants were randomized either to a high-intensity aerobic exercise or stretching control group. The aerobic group exercised under the supervision of a fitness trainer at 75% to 85% of heart rate reserve for 45 to 60 min/d, 4 d/wk for 6 months. The control group carried out supervised stretching activities according to the same schedule but maintained their heart rate at or below 50% of their heart rate reserve. Before and after the study, glucometabolic and treadmill tests were performed and fat distribution was assessed using dual-energy x-ray absorptiometry. At baseline, month 3, and month 6, blood was collected for assay and cognitive tests were administered.Performance measures on Symbol-Digit Modalities, Verbal Fluency, Stroop, Trails B, Task Switching, Story Recall, and List Learning. Fasting plasma levels of insulin, cortisol, brain-derived neurotrophic factor, insulinlike growth factor-I, and beta-amyloids 40 and 42.Six months of high-intensity aerobic exercise had sex-specific effects on cognition, glucose metabolism, and hypothalamic-pituitary-adrenal axis and trophic activity despite comparable gains in cardiorespiratory fitness and body fat reduction. For women, aerobic exercise improved performance on multiple tests of executive function, increased glucose disposal during the metabolic clamp, and reduced fasting plasma levels of insulin, cortisol, and brain-derived neurotrophic factor. For men, aerobic exercise increased plasma levels of insulinlike growth factor I and had a favorable effect only on Trails B performance.This study provides support, using rigorous controlled methodology, for a potent nonpharmacologic intervention that improves executive control processes for older women at high risk of cognitive decline. Moreover, our results suggest that a sex bias in cognitive response may relate to sex-based differences in glucometabolic and hypothalamic-pituitary-adrenal axis responses to aerobic exercise.

    View details for DOI 10.1001/archneurol.2009.307

    View details for Web of Science ID 000273535700010

    View details for PubMedID 20065132

    View details for PubMedCentralID PMC3056436

  • Statin Users Without an APOE-epsilon 4 Allele have Increased Insulin Resistance JOURNAL OF ALZHEIMERS DISEASE VanFossen, B. T., Watson, G., Baker, L. D., Rhoads, K. W., Cholerton, B. A., Reger, M. A., Plymate, S. R., Schellenberg, G., Craft, S. 2010; 19 (4): 1149–53

    Abstract

    The present study examined the relationships among statin use, APOE genotype, and insulin resistance as measured by the homeostasis model assessment of insulin resistance (HOMA-IR) in healthy older adults. APOE epsilon4- (i.e., not having an epsilon4 allele) statin users had higher HOMA-IR values compared with epsilon4+/statin users (p=0.0169), and with non-users who were epsilon4- (p=0.0003) or epsilon4+ (p=0.0006). These results suggest that statin use may modulate insulin levels for individuals without an APOE epsilon4 allele.

    View details for DOI 10.3233/JAD-2009-1319

    View details for Web of Science ID 000276619700005

    View details for PubMedID 20308781

    View details for PubMedCentralID PMC2945621

  • Effects of Insulin and Octreotide on Memory and Growth Hormone in Alzheimer's Disease JOURNAL OF ALZHEIMERS DISEASE Watson, G., Baker, L. D., Cholerton, B. A., Rhoads, K. W., Merriam, G. R., Schellenberg, G. D., Asthana, S., Cherrier, M., Craft, S. 2009; 18 (3): 595–602

    Abstract

    Both insulin alone and the somatostatin analogue octreotide alone facilitate memory in patients with Alzheimer's disease (AD). Since octreotide inhibits endogenous insulin secretion, the cognitive effects of insulin and octreotide may not be independent. This study tested the individual and interactive effects of insulin and octreotide on memory and plasma growth hormone (GH) levels in older adults. Participants were 16 memory-impaired (AD = 7, amnestic mild cognitive impairment = 9; apolipoprotein E [APOE] epsilon4- [no epsilon4 alleles] = 9, epsilon4+ [1-2 epsilon4 alleles] = 7), and 19 cognitively-intact older adults (APOE epsilon4- = 17, epsilon4+ = 1). On separate days, fasting participants received counterbalanced infusions of: 1) insulin (1 mU.kg(-1).min(-1)) and dextrose to maintain euglycemia; 2) octreotide (150 microg/h); 3) insulin, dextrose, and octreotide; or 4) saline. Story recall was the principal endpoint. Insulin alone facilitated delayed recall for epsilon4- patients, relative to epsilon4+ patients (P = 0.0012). Furthermore, epsilon4- patients with higher Mattis Dementia Rating Scale (DRS) scores had greater octreotide-induced memory facilitation (P = 0.0298). For healthy adults, octreotide facilitated memory (P = 0.0122). Unexpectedly, hyperinsulinemia with euglycemia increased GH levels in healthy controls (P = 0.0299). Thus, insulin and octreotide appear to regulate memory in older adults. APOE epsilon4 genotype modulates responses to insulin and octreotide. Finally, insulin may regulate GH levels during euglycemia.

    View details for DOI 10.3233/JAD-2009-1165

    View details for Web of Science ID 000272860100011

    View details for PubMedID 19625744

    View details for PubMedCentralID PMC2842464

  • Cognitive function over time in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT) - Results of a randomized, controlled trial of naproxen and celecoxib ARCHIVES OF NEUROLOGY Martin, B. K., Szekely, C., Brandt, J., Piantadosi, S., Breitner, J. C. S., Craft, S., Evans, D., Green, R., Mullan, M., ADAPT Res Grp 2008; 65 (7): 896–905

    Abstract

    Observational studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs.To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults.Randomized, double-masked chemoprevention trial.Six US memory clinics.Men and women aged 70 years and older with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment.Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly allocated in a ratio of 1:1:1.5, respectively.Seven tests of cognitive function and a global summary score measured annually.Longitudinal analyses showed lower global summary scores over time for naproxen compared with placebo (- 0.05 SDs; P = .02) and lower scores on the Modified Mini-Mental State Examination over time for both treatment groups compared with placebo (- 0.33 points for celecoxib [P = .04] and - 0.36 points for naproxen [P = .02]). Restriction of analyses to measures collected from persons without dementia attenuated the treatment group differences. Analyses limited to measures obtained while participants were being issued study drugs produced results similar to the intention-to-treat analyses.Use of naproxen or celecoxib did not improve cognitive function. There was weak evidence for a detrimental effect of naproxen.

    View details for Web of Science ID 000257596100004

    View details for PubMedID 18474729

    View details for PubMedCentralID PMC2925195

  • Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults JOURNAL OF ALZHEIMERS DISEASE Reger, M. A., Watson, G., Green, P. S., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Cherrier, M. M., Schellenberg, G. D., Frey, W. H., Craft, S. 2008; 13 (3): 323–31

    Abstract

    Intranasal insulin administration raises central nervous system (CNS) insulin levels in humans and acutely facilitates verbal memory in patients with Alzheimer's disease (AD), an effect that may differ by APOE genotype. The purpose of this study was to examine the cognitive dose response curves for intranasal insulin administration, and determine whether the effects of insulin differ between participants with (epsilon4+) and without (epsilon4-) the APOE- epsilon4 allele. On separate mornings, 33 memory-impaired adults with AD or amnestic mild cognitive impairment and 59 normal adults each underwent five intranasal treatment conditions consisting of insulin (10, 20, 40, or 60 IU) or placebo. Cognition was tested 15-minutes post-treatment, and blood was acquired at baseline and 45-minutes post-treatment. Plasma insulin and glucose levels were unaffected by treatment. Insulin administration facilitated recall on two measures of verbal memory in memory-impaired epsilon4- adults, with performance generally peaking at 20 IU. In contrast, memory-impaired epsilon4+ subjects demonstrated a relative decline in verbal memory. Insulin also differentially modulated plasma amyloid-beta for memory-impaired subjects and normal controls, effects that again differed by APOE genotype. These findings suggest that groups with different genetic risks for AD may show differential dose-response curves following intranasal insulin administration.

    View details for Web of Science ID 000256229900009

    View details for PubMedID 18430999

    View details for PubMedCentralID PMC2804944

  • Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease NEUROBIOLOGY OF AGING Watson, G. S., Bernhardt, T., Reger, M. A., Cholerton, B. A., Baker, L. D., Peskind, E. R., Asthana, S., Plymate, Frolich, L., Craft, S. 2006; 27 (1): 38–41

    Abstract

    We assessed the effects of induced hyperinsulinemia on plasma and cerebrospinal fluid (CSF) levels of norepinephrine (NE) and on cognition for patients with Alzheimer's disease (AD) and normal older adults. For normal adults, insulin increased plasma and CSF NE levels; also, recall for paraphrased details of a story improved as CSF NE levels increased. Mental control was positively correlated with CSF levels of NE for patients. These findings demonstrate that raising peripheral insulin levels can modulate CNS NE levels and suggest that insulin-stimulated increases in NE may modulate cognitive functions.

    View details for DOI 10.1016/j.neurobiolaging.2004.11.011

    View details for Web of Science ID 000234355800006

    View details for PubMedID 16298239

  • Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone - A preliminary study AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY Watson, G. S., Cholerton, B. A., Reger, M. A., Baker, L. D., Plymate, Asthana, S., Fishel, M. A., Kulstad, J. J., Green, P. S., Cook, D. G., Kahn, S. E., Keeling, M. L., Craft, S. 2005; 13 (11): 950–58

    Abstract

    Insulin resistance (impaired insulin action) has been associated with Alzheimer disease (AD) and memory impairment, independent of AD. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists improve insulin sensitivity and regulate in-vitro processing of the amyloid precursor protein (APP). Authors evaluated the effects of the PPAR-gamma agonist rosiglitazone on cognition and plasma levels of the APP derivative beta-amyloid (Abeta) in humans.In a placebo-controlled, double-blind, parallel-group pilot study, 30 subjects with mild AD or amnestic mild cognitive impairment were randomized to a 6-month course of rosiglitazone (4 mg daily; N = 20) or placebo (N = 10). Primary endpoints were cognitive performance and plasma Abeta levels.Relative to the placebo group, subjects receiving rosiglitazone exhibited better delayed recall (at Months 4 and 6) and selective attention (Month 6). At Month 6, plasma Abeta levels were unchanged from baseline for subjects receiving rosiglitazone but declined for subjects receiving placebo, consistent with recent reports that plasma Abeta42 decreases with progression of AD.Findings provide preliminary support that rosiglitazone may offer a novel strategy for the treatment of cognitive decline associated with AD. Future confirmation in a larger study is needed to fully demonstrate rosiglitazone's therapeutic potential.

    View details for DOI 10.1176/appi.ajgp.13.11.950

    View details for Web of Science ID 000233169300005

    View details for PubMedID 16286438

  • Effects of rosiglitazone treatment on serum amyloid-beta 1-40 and 1-42 in patients with early Alzheimer's disease Kulstad, J., Green, P. S., Cook, D. G., Watson, G. S., Reger, M., Cholerton, B., Baker, L. D., Plymate, Asthana, S., Fishel, M., Kahn, S. E., Craft, S. ELSEVIER SCIENCE INC. 2004: S354–S355
  • Insulin effects on plasma beta-amyloid levels in normal adults and patients with AD Craft, S., Kulstad, J., Green, P., Cook, D., Watson, G. S., Baker, L. D., Reger, M., Cholerton, B., Asthana, S., Plymate, S. ELSEVIER SCIENCE INC. 2004: S35
  • Rosiglitazone preserves cognitive functions in patients with early Alzheimer's disease Watson, G. S., Reger, M. A., Cholerton, B. A., Asthana, S., Baker, L. D., Rhoads, K. W., Plymate, Fishel, M. A., Kahn, S. E., Craft, S. ELSEVIER SCIENCE INC. 2004: S83
  • Hyperinsulinemia predicts cognitive performance for normal older adults and for patients with Alzheimer's disease Baker, L. D., Cholerton, B., Reger, M., Watson, S., Chapman, D., Enstrom, K., Hyde, K., Craft, S. ELSEVIER SCIENCE INC. 2004: S110
  • Cortisol infusion attenuates insulin's facilitation of verbal memory in patients with Alzheimer's disease Reger, M., Watson, G. S., Cholerton, B., Baker, L. D., Asthana, S., Plymate, S., Wilkinson, C. W., Peskind, E. R., Enstrom, K., Hyde, K., Belongia, D., Craft, S. ELSEVIER SCIENCE INC. 2004: S168–S169
  • The effect of insulin and octreotide on verbal memory and attention in cognitively impaired older adults Rhoads, K., Cholerton, B., Baker, L. D., Reger, M., Watson, G. S., Plymate, S., Fishel, M. A., Asthana, S., Enstrom, K., Keeling, M. ELSEVIER SCIENCE INC. 2004: S169
  • Raloxifene enhances cognitive function for postmenopausal women with Alzheimer's disease Lane, N. J., Baker, L. D., Gleason, C. E., Koscik, R., Cholerton, B., Craft, S., Slattery, A. M., Ohrt, T. L., Asthana, S. ELSEVIER SCIENCE INC. 2004: S220
  • Alzheimer's disease: Potential beneficial effects of estrogen on performance-based battery of physical function skills for older women Slattery, A. M., Ohrt, T. L., Gleason, C. E., Helmers, Cholerton, B., Lofgreen, C., Baker, L. D., Craft, S., Asthana, S. ELSEVIER SCIENCE INC. 2004: S333
  • Agraphic changes in mild cognitive impairment Hale, C., Baker, L. D., Reger, M., Rhoads, K., Cholerton, B., Watson, G. S., Craft, S. ELSEVIER SCIENCE INC. 2004: S338
  • Effects of beta-hydroxybutyrate on cognition in memory-impaired adults NEUROBIOLOGY OF AGING Reger, M. A., Henderson, S. T., Hale, C., Cholerton, B., Baker, L. D., Watson, G. S., Hyde, K., Chapman, D., Craft, S. 2004; 25 (3): 311–14

    Abstract

    Glucose is the brain's principal energy substrate. In Alzheimer's disease (AD), there appears to be a pathological decrease in the brain's ability to use glucose. Neurobiological evidence suggests that ketone bodies are an effective alternative energy substrate for the brain. Elevation of plasma ketone body levels through an oral dose of medium chain triglycerides (MCTs) may improve cognitive functioning in older adults with memory disorders. On separate days, 20 subjects with AD or mild cognitive impairment consumed a drink containing emulsified MCTs or placebo. Significant increases in levels of the ketone body beta-hydroxybutyrate (beta-OHB) were observed 90 min after treatment (P=0.007) when cognitive tests were administered. beta-OHB elevations were moderated by apolipoprotein E (APOE) genotype (P=0.036). For 4+ subjects, beta-OHB levels continued to rise between the 90 and 120 min blood draws in the treatment condition, while the beta-OHB levels of 4- subjects held constant (P<0.009). On cognitive testing, MCT treatment facilitated performance on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) for 4- subjects, but not for 4+ subjects (P=0.04). Higher ketone values were associated with greater improvement in paragraph recall with MCT treatment relative to placebo across all subjects (P=0.02). Additional research is warranted to determine the therapeutic benefits of MCTs for patients with AD and how APOE-4 status may mediate beta-OHB efficacy.

    View details for DOI 10.1016/S0197-4580(03)00087-3

    View details for Web of Science ID 000189229600006

    View details for PubMedID 15123336

  • The relationship between neuropsychological functioning and driving ability in dementia: A meta-analysis NEUROPSYCHOLOGY Reger, M. A., Welsh, R. K., Watson, G. S., Cholerton, B., Baker, L. D., Craft, S. 2004; 18 (1): 85–93

    Abstract

    A meta-analysis of 27 primary studies was conducted to examine the relationship between neuropsychological functioning and driving ability for adults with dementia. When studies using a control group were included, the relationship between cognitive measures and on-road or non-road driving measures was significant for all reported domains; mean correlations ranged from.35 to.65. Caregiver reports of driving ability and cognitive variables were correlated significantly only on measures of mental status and visuospatial skills. When studies using a control group were excluded, moderate mean correlations were observed for visuospatial skills and on-road or non-road measures, and for mental status with non-road tests. Other effects were small or nonsignificant. Implications for basing driving recommendations on neuropsychological testing are discussed.

    View details for DOI 10.1037/0894-4105.18.1.85

    View details for Web of Science ID 000188398100009

    View details for PubMedID 14744191

  • Estrogen and Alzheimer's disease - The story so far DRUGS & AGING Cholerton, B., Gleason, C. E., Baker, L. D., Asthana, S. 2002; 19 (6): 405–27

    Abstract

    The ovarian hormone estrogen has long been used to treat the physical symptoms of menopause and to aid in the prevention of osteoporosis in postmenopausal women. Cumulative evidence from basic science and clinical research suggests that estrogen also plays a significant neuromodulatory and neuroprotective role. The numerous estrogenic effects in the brain include the modulation of synaptogenesis, increased cerebral blood flow, mediation of important neurotransmitters and hormones, protection against apoptosis, anti-inflammatory actions, and antioxidant properties. These multiple actions in the central nervous system support estrogen as a potential treatment for the cognitive decline associated with Alzheimer's disease (AD), the most common form of dementia. Evidence from epidemiological studies supports enhanced cognitive function in women with AD taking estrogen replacement therapy (ERT) as well as a reduced risk for developing AD in healthy women receiving ERT. Additional clinical evidence suggests that estrogen may modulate specific cognitive functions such as working memory and verbal learning and memory. However, results from more recent controlled trials have not consistently shown a beneficial effect of estrogen on the cognitive function of women with AD. Future research should focus on examining the influence of multiple potential mediators of ERT including the route of estrogen administration, form of estrogen (conjugated estrogens vs estradiol), duration of treatment, opposed versus unopposed estrogen and the use of estrogen analogues. Further, sensitive neuropsychological measures may provide more detailed information concerning the specific effects of estrogen on cognitive function. These important issues must be addressed in order to establish the role of estrogen for the prevention and treatment of AD in women.

    View details for DOI 10.2165/00002512-200219060-00002

    View details for Web of Science ID 000177666800002

    View details for PubMedID 12149049